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ABBREVIATIONS 
ACE: Angiotensin-converting enzyme 
AGE: Advanced glycation end products 
AHS: Amplification hydrogel solution 
Ang II: Angiotensin II  
AT1R: Angiotensin type 1 receptor 
AT2R: Angiotensin type 2 receptor 
AZAN: Heidenhain's AZAN trichrome staining 
BSA: Bovine serum albumin 
CD2AP: CD2-associated protein 
CTRL: Control 
D: diabetes 
DBP: Diastolic blood pressure 
D-HBP: Diabetic high blood pressure 
DN: Diabetic nephropathy 
DSS: Dextran Sulfate Sodium 
EM: Electron microscopy 
ExFISH: Expansion fluorescent in-situ hybridization 
ExM: Expansion Microscopy 
FF: Filtration flow 
FHH: Fawn Hooded Hypertensive 
FITC-Sinistrin: fluorescein-isothiocyanate labeled sinistrin 
FPE: Foot Process Enfacement 
FPs: Foot process 
FSD: Filtration slit density 
FSGS: Focal segmental glomerulosclerosis 
GDA: Glutaraldehyde 
GFB: Glomerular filtration barrier 
GFR: Glomerular filtration rate 
GLUT-2: Glucose transporter 2 
GMB: Glomerular basement membrane 
HBP: High blood pressure 
H&E: Hematoxylin and Eosin staining 
I3C: Indole-3-Carbinol 
IHC: Immunohistochemistry 
iExM: Iterative expansion Microscopy  
MAP: Magnified analysis of the proteome 
MCs: Megangial cells 
PAS: Periodic acid-Schiff 
PBS: Phosphate buffered saline 
PBST: Phosphate buffered saline triton 
PFA: Paraformaldehyde 
PTA: Phosphotungstic acid 
RAAS: Renin-angiotensin-aldosterone system 
Rac1: Ras-related C3 botulinum toxin substrate 1 
RAGE: Receptor for advanced glycation end products 
RAS: Renin-Angiotensin System 
RI: Refractive index 
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ROS: Reactive oxygen species 
SD: Slit diaphragm 
SDS: Sodium Dodecyl Sulfate 
SHHF: Spontaneously hypertensive heart failure 
SHR: spontaneously hypertensive rats 
SIM: Structured Illumination microscopy 
STZ: Streptozotocin or streptozocin 
TFPC6: Transient receptor potential cation channel 
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TRPC5: Short transient receptor potential channel 5 
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1 INTRODUCTION 
1.1 Structure and function of the glomerular filtration barrier in the kidney                                                                                                                                                                                                                  
The kidneys are two bean-shaped organs that receive blood from the paired renal 
arteries, while blood exits through the paired renal veins. Each kidney is connected to 
a ureter, which transports excreted urine to the bladder, a hollow muscular organ 
[Figure-1A]. Kidneys are involved in several vital functions in the human body, such 
as the formation of urine, hormone secretion, blood pressure regulation, acid-base 
balance, and the regulation of osmolarity. Urine formation is a result of filtration, 
reabsorption, secretion and excretion processes in the nephron, which is the smallest 
functional unit of the kidney. Each nephron consists of glomeruli, proximal tubules, a 
loop of Henle and distal tubules [Figure-1B]. 
 
 
 
Figure-1: Representation of kidney anatomy. A- Kidney crossection; a- Renal artery, b- Renal vein, c- 
Renal pyramid, d- Renal cortex and e- Renal pelvis and Ureter. B- Anatomic representation of a 
nephron; f- Intertubular artery, g- Intertubular vein, h- Glomerular capillaries, i- Glomerular capsule, j- 
Proximal convoluted tubule, k- Descending part of loop of Henle, l- Ascending part of loop of Henle, m- 
Distal convoluted tubule and n- Collecting duct. 
The glomeruli are composed of a tuft of capillaries and a surrounding structure called 
the Bowman’s capsule, which is connected to the proximal convoluted tubule. The 
glomerular tuft architecture is supported by the mesangium, which consists of 
Introduction 
 
9 
 
mesangial cells that fill the space between capillaries and are the main force for 
folding the capillaries1 [Figure-2A]. The glomerular filtration barrier (GFB) is formed 
in three layers: the fenestrated capillary endothelium (fenestrae) at the inner wall of 
the capillaries, the glomerular basement membrane (GBM) and the podocytes, highly 
sophisticated, terminally differentiated epithelial cells with a complex structure 
[Figure-2B]. Each podocyte consists of a large cell body, freely floating above the 
capillaries on the urinary side, and large primary foot processes extending into 
numerous secondary foot processes (FPs) that are linked to the GBM by integrins 
and wrap around the capillaries. Secondary FPs of different podocytes interdigitate 
with each other and are connected by the slit diaphragm (SD), where nephrin is one 
of the main constituents [Figure-2C]. The internal nephrin domain binds to podocin 
and CD2AP at the insertion site of the SD. The external domain of one nephrin is 
connected to another nephrin’s external domain, extending from the FP of another 
podocyte2 [Figure-2C]. The SD has signaling functions but also represents a major 
molecular filter with a slit size of 5x 14 nm3. The filtration barrier filters the urine from 
the blood and does not allow blood-derived proteins to leak into urine4. FP 
morphology is highly dependent on the architecture of the actin cytoskeleton. 
The three layers of the GFB depend on and closely communicate with each other5. 
Damage to any of the layers can cause leakage of the GFB that could result in the 
presence of protein and albumin, a blood serum protein, in the urine. Detection of 
protein or albumin in the urine is called proteinuria and albuminuria, respectively. 
Proteinuria and albuminuria are vital clinical signs for the evaluation of the kidney’s 
function. The degree of filtration is determined by a calculation called glomerular 
filtration rate (GFR)6.  
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Figure-2: Graphic illustration of the glomerulus and the filtration barrier. A- Scheme illustrates the 
pathological changes in glomeruli during diabetic nephropathy. B- 3 layers of the glomerular filtration 
barrier:  fenestrated epithelial cells with pores enabling filtration, the glomerular basement membrane 
(GBM) and the podocyte foot processes (FP) fixed to the GBM by laminin and integrin. Nephrin is the 
main constituent of the slit diaphragm (SD) and attaches at its internal domain to podocin and CD2AP 
at the insertion site of SD. The direction of filtration is from the capillary lumen to the Bowman’s space. 
Fenestrated epithelial cells, the GMB, the slit membrane and FPs are involved in the filtration process. 
C- Podocyte morphology with a large cell body, primary foot processes and interdigitating secondary 
foot processes.  
 
1.2 Glomerular lesions in diabetic nephropathy and hypertension 
Many diseases affect kidney function by attacking the glomeruli resulting in 
glomerular disease. It may be the direct consequence of an infection or a drug with 
renal toxicity or can result from a condition which affects the entire body, like diabetes 
or hypertension. Many different kinds of diseases can lead to swelling or scarring of 
the nephron or glomerulus7. However, sometimes the glomerular disease is 
idiopathic, meaning that it occurs without an apparent associated disease. 
1.2.1 Diabetic nephropathy 
Discoveries of a metabolic disease related to renal failure are ancient. Ancient Indian 
and Chinese physicians mentioned the diagnosis of sweet urine disease (sugar cane 
urine) as early as 300 BC and 600 AD8. In Europe, the sweet taste of urine due to 
diabetes was first mentioned by Thomas Willis in 16749. Sugar was then discovered 
to be the sweet compound in urine by Matthew Dobson in 17769. In 1880, Etienne 
A 
B 
C 
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Lancereaux improved the understanding of diabetic nephropathy (DN) by suggesting 
that diabetes may result in proteinuria in obese individuals. Today, DN is at the 
center stage of research, since increased wealth worldwide has dramatically 
increased the frequency of Type-2 diabetic patients. DN is one of the most serious 
complications in diabetic patients10, and 30 – 40 % of Type-1 and Type-2 diabetic 
patients develop DN11-13. The first clinical signs of DN are hyperfiltration and 
albuminuria which indicate leakage of the filtration barrier. Hyperfiltration is closely 
linked with glomerular hypertrophy. DN typically includes glomerulopathy and 
tubulopathy. Although the disease progression more closely correlates with the 
degree of tubulopathy than with glomerular lesions, it is still unclear whether it is 
molecular and functional alterations in the glomeruli or tubules that initiates the 
disease. Histopathological changes include thickening of the glomerular and tubular 
basement membranes and mesangial expansion, which is partially caused by the 
depositing of worn-out GBM in the mesangium14. Nodular Kimmelstiel-Wilson-lesions 
in glomeruli are an advanced feature of human DN and consist of hyaline, fibrosis 
and vascular alterations, which results in a decline in the GFR. Albuminuria is often 
associated with tremendous changes in podocyte shape due to foot process 
effacement (FPE). FPE is characterized by the retraction, widening and shortening of 
the FPs, and is regarded as a protective response to prevent podocyte detachment 
from the GBM3, 15. The early stages of FPE are reversible. However, once FPE is 
complete, podocytes are mainly attached to the GBM by their cell bodies, having lost 
all of their FPs. Shear stress, produced by filtrate flow through the GBM during 
hyperfiltration, is a significant challenge specifically for podocytes and can cause 
them to disconnect from the GBM15. Podocyte loss into the urine is characteristic of 
DN and correlates with albuminuria and the progression of DN16.  
1.2.2 Hypertensive renal diseases 
In the 20th century, Franz Volhard suggested that kidney diseases are not only due to 
diabetes but can be strongly influenced by accompanying diseases (cardiac disease, 
tuberculosis, etc.)17-19. The first critical study showing that high blood pressure (HBP) 
promotes albuminuria, was completed by Mogensen. He revealed that HBP 
increases albuminuria and decreases the GFR20. Later, they have clearly shown that 
antihypertensive treatment inhibits the progression of DN21. A key determinant in 
HBP is Angiotensin II (Ang II), initially termed hypertensin, which was first described 
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in 1940 by Page. This opened a new era for the discovery of novel drugs targeting 
the renin-angiotensin system (RAS) for renal disease 19, 22, 23. Hypertension is one of 
the most common diseases worldwide. Although the exact reason for hypertension 
often cannot be explained, it produces progressive health problems since it can 
cause stroke, heart disease, eye problems and kidney failure if untreated24, 25. The 
risk factors double if hypertension occurs alongside with other diseases such as 
obesity25, 26 and diabetes 27, 28. 
HBP causes arteries around the kidneys to narrow, weaken or harden. These 
damaged arteries are no longer able to deliver enough blood to the kidney tissue. 
Long term glomerular ischemia can damage the endothelium, commonly known as 
the blood vessel lining. This may lead to a build-up of plaques that may be 
accumulated in the renal arteries causing stenosis and ischemic kidney disease29, 30. 
In this situation, the kidney suffers from inadequate blood flow due to being supplied 
by the narrowed renal artery, which in turn causes the size of the kidneys to 
decrease. Other consequences include arterial stiffening, due to the gradual 
breakdown of elastic fibers, and thickening of the intima (the innermost layer of a 
blood vessel). An alternative mechanism of hypertensive nephropathy is prolonged 
glomerular hypertension30. These can occur simultaneously or alone. The current 
hypothesis is that hypertension results in the sclerosis of the glomeruli that ultimately 
leads to reduced kidney function. Within the unaffected nephrons, the preglomerular 
arterioles vasodilate as a compensatory mechanism to increase blood flow to the 
kidney and increase glomerular filtration across undamaged glomeruli7.   
In benign nephrosclerosis, the alterations are gradual and progressive; however, 
there can be sufficient reserve kidney capacity to maintain sufficient kidney function 
for many years. The large renal arteries exhibit intimal thickening, medial hypertrophy 
and duplication of the elastic layer. The alterations in small arterioles include hyaline 
arteriolosclerosis (accumulation of hyaline, collagenous material) 29, 31, which leads to 
glomerular collapse (wrinkling and thickening of capillary basement membranes and 
the collapse of the capillary lumen) and hardening (glomeruli exhibit sclerosis and 
increases in the mesangial matrix). The degree of damage correlates with the degree 
of glomerular filtration deficits. Malignant nephrosclerosis occurs in the presence of 
malignant hypertension (when diastolic BP > 130mmHg). Vessels feature intimal 
thickening, fibrinoid necrosis, red blood cell fragmentation, extravasation and 
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thrombosis. These changes create an exaggerated, layered appearance (onion 
skinning) 7, 29. 
1.3 The Renin Angiotensin System in diabetic nephropathy and 
hypertension 
The RAS has been well known for more than a hundred years as a hormonal 
cascade, regulating fluid and electrolyte balance, as well as blood pressure. The 
angiotensin peptides are produced in a cascade initiated by renin, which is generated 
as preprorenin in juxtaglomerular cells of the kidney. Renin cleaves liver-derived 
angiotensinogen into Ang I, a decapeptide, which is then processed by angiotensin-
converting enzyme (ACE) into Ang II32. Ang II is the crucial component of this system 
and binds to two G-protein coupled receptors, the AT1R and AT2R [Figure-3A].. 
Most of the well-known effects of Ang II are transmitted via the AT1R, which is the 
primary Ang II receptor in the adult kidney. The AT1R utilizes various signaling 
cascades, which functionally crosstalk with other signaling pathways33 [Figure-3B]. It 
is now well established that, besides the classic systemic RAS, an independently 
regulated tissue RAS acting paracrine exist. Recently there are evidence for 
intracrine acting RAS, which are able to produce Ang II within cells and express Ang 
II receptors on intracellular organelles34, 35. In addition, new components of the 
system were found including ACE2, Angiotensin (1-7) and the mas receptor which, 
together with the AT2R, belong to the protective arm of the RAS and often counter-
regulate AT1R transmitted Ang II effects [Figure-3A].  
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Figure-3: Renin-Angiotensin System (RAS). A- Peptides, enzymes and receptors of the RAS and 
transmitted effects.  B- Classical AT1R signaling pathways and their interaction with other pathways 
*(Forrester et al. 2018). 
 
The kidney is one of the most critical targets of the RAS. Ang II not only regulates 
renal function indirectly via its hemodynamic actions, but also by direct actions on 
renal cells independent of hemodynamic effects. Thus, inhibiting Ang II production or 
blocking AT1Rs is currently the first-line therapy in DN and hypertension. However, 
the complex underlying mechanisms have not yet been resolved. Within the 
A 
B 
A 
B 
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glomerulus, AT1Rs are found on mesangial cells and stimulate hypertrophic and 
proliferative growth36. Podocytes express all components of the RAS, allowing 
independent intracrine and paracrine Ang II action37. Local renal Ang II production 
results in Ang II levels in the nanomolar range within the Bowmanʼs space and the 
proximal tubules which is roughly 1000-times higher than in the plasma, where Ang II 
levels are in the femtomolar range38. It has previously been shown that AT1R 
overexpression in podocytes causes slowly progressing FSGS and renal failure39. 
The underlying mechanisms of AT1R action in the podocytes have been intensively 
studies. It has been shown that AT1Rs in podocytes mediate the Ang II-induced 
stimulation of the TRPC5/rac1/ROS pathway. Rac1 also leads to a reduction of 4-
actinin and ezrin/radixin/moesin phosphorylation40-42. 4-actinin and the 
ezrin/radixin/moesin complex regulate the attachment of membrane proteins to the 
actin cytoskeleton. Therefore, the AT1R induced pathway leads to a reorganization of 
the actin cytoskeleton and SD protein redistribution. In parallel, ROS decreases 
RhoA activity resulting in a phenotypic switch in podocytes from a stable to a 
migratory phenotype that, in vivo, might promote the detachment of podocytes in 
stress situations39, 40, 43 [Figure-4]. The depletion of podocytes is an important feature 
in the progression of DN. DN amplifies AT1R signaling in podocytes by specifically 
stimulating the renal and the intra-podocyte RAS37, 41.  
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Figure-4: AT1R mediated signaling in podocytes. High glucose and mechanical strain stimulate AT1R 
mediated Angiotensin II (Ang II) signaling in podocytes affecting migratory phenotype and 
cytoskeleton rearrangement. * This figure originally published by Marquez, E. et al. 2015 
 
1.4 Rodent models for diabetic nephropathy and hypertension 
Developments and increases in drug discovery studies opened up new questions in 
the field, as the safety novel drugs are never guaranteed. To be able to surpass this 
lack of clarity, as well as ethical issues, animal experiments became a gold standard 
for drug testing in Europe and other countries. Initially, the main problem was finding 
the right animals to use in research.  Since rodents do not usually develop kidney 
impairments, they were not the best model to study the kidney44. Subsequently, 
scientists have found different ways to induce renal disease in rodents by inbreeding, 
chemical inducements and genetic manipulations. 
Introduction 
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1.4.1 Diabetic nephropathy 
There are now many animal models used in diabetic research (both Type 1 and Type 
2 Diabetes Mellitus), which can be categorized into two main classes as genetically 
modified animals and chemically induced animals.  
Genetically modified rodent models can be subcategorized according to which type of 
diabetes they are meant to model. BB rats 45-47, LEW 1AR1/ -iddm rats48, 49, 
Monobase Diabetic mice50 and Akita mice51, 52 are the genetically modified rodent 
models developed to study Type-1 diabetes mellitus. ZDF rats53 and Goto-Kakizaki 
rats54, 55 are the genetically modified rats developed to study Type-2 diabetes 
mellitus. A major limitation of these models was their resistance to developing DN. 
Thus, these rats were subsequently cross-bred with other disease models. In rats, it 
has been shown that the AT1R is responsible for post-glomerular vasoconstriction 
and is increased in the renal cortex of obese Zucker rats 56. Overall, increases in 
circulating RAS elements, due to excess amount of adipose tissue in obesity, 
stimulates renal AT1R expression and leads to efferent arteriolar vasoconstriction 
and elevated glomerular pressure which increases filtration flow (FF)57. Another 
widely applied method is the chemical induction of diabetes type 1 by injection of 
streptozotocin (or alloxan) (STZ) into healthy animals 58. Importantly, this model is 
still the most widely used one. STZ is a chemical compound that is an analog of N-
acetylglucosamine. It is transported into insulin-producing B-cells by GLUT-2, where 
it leads to apoptosis by inhibiting the activity of O-acetlyglucosaminese59. STZ was 
first described as an antibiotic60, and was marketed as an antibacterial compound. 
Afterward, it was used for the treatment of malignant islet-cell tumors61 until a study 
showed that STZ is toxic to insulin-producing cells specifically62. 
Today, STZ is the most commonly used chemical to induce diabetes for research 
purposes. Hundreds of experiments have made use of STZ. Some scientists prefer 
the injection of multiple small doses of STZ to induce diabetes while others prefer to 
inject a single large dose63-68. The route of administration also varies among 
scientists. Generally, the preferred way is either intravenous (i.v) or intraperitoneal 
(i.p) injection of the compound. In spite of these variations in application, in practice, 
there is no proven difference in the degree of diabetes. 
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STZ-diabetic rodent models only develop the earliest features of DN. Some lines, like 
the Sprague Dawley rat, are almost entirely resistant to renal damage from STZ 
diabetes. 
1.4.2 The ZSF1 rat 
The ZSF-1 rat (ZSF1-Lepr-fa-Lepr-cp/Crl Hybrid) is based on the hypertensive SHR 
rat, into which both the fa mutant allele, from the sugar diabetic rat ZDF with a leptin 
receptor defect fa/fa69, and the cp mutant allele, from the JCR:LA cp/cp rat with the 
leptin receptor defect cp/cp, were crossed in70. Due to the combination of all three 
defects, the ZSF1 rat spontaneously develops Type 2 diabetes, hypertension, cardiac 
dysfunction, obesity and severe renal damage. Disease progression is associated 
with oxidative stress and increased AGE and RAGE71. Thus, in addition to 
hyperglycemia these rats suffer from a metabolic syndrome, which reflect the 
situation in human DN patients. Obese patients exhibit increased kidney and 
glomerular size, even in the absence of detectable changes in renal function 72. 
Increased GFR is also detectable in obese patients (with or without diabetes mellitus) 
due to hemodynamic changes 73. Hemodynamic changes in obesity increase the risk 
of increased salt sensitivity, which activates the RAS74, 75. Furthermore, adipose 
tissue can activate RAS and induce hypertension, which may result in proteinuria 76.  
1.4.3 Hypertension 
The spontaneously hypertensive rat (SHR) was the first rat model of hypertension. It 
was developed by Okamoto and colleagues in the 1960s and was widely used for 
cardiovascular research77. The SHR starts to develop hypertension from around 5–6 
weeks of age, and systolic pressure reaches between 180 and 200 mmHg78, 79. In 
this model, scientists have shown that hypertension accelerates microalbuminuria80, 
81. Leonarda B. Sablay and his colleagues in 1986 in the USA investigated the effect 
of hypertension on proteinuria, creatinine clearance and renal histology in 
hypertensive diabetic rats. In the same year, A.E. Doyle and the colleagues in 
Australia used the same experimental setup to evaluate the effect of hypertension on 
diabetes. Both experiments showed that hypertension accelerates proteinuria and 
albuminuria 82, 83. Thereafter, many hypertensive models have been developed. 
Among the genetic models the SHR77, Sabra hypertensive84, 85, DSS86, FHH87, Lyon 
hypertensive88, 89 and the Milan hypertensive rats90 are the most commonly used 
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ones. Another approach is the chemical induction of hypertension by the chronic 
infusion of Ang II via osmotic pumps91-93. 
1.4.4 The TGR Cyp1a1Ren2 rat 
The development of gene manipulation techniques opened the possibility of 
developing more sophisticated hypertensive models. The first transgenic rat model 
was developed by Mullins‘ group in 1990, in which overexpression of the mouse renin 
2 gene caused malignant hypertension94. This rat line was often used as a model for 
DN after induction of STZ-diabetes. However, they developed a malignant phase of 
hypertension, which limited the usefulness for the study of DN95, 96. The Mullins group 
later developed a more sophisticated transgenic rat carrying the renin 2 gene under 
the control of the inducible Cytochrome P4501a1 promoter whose activity is tightly 
controllable through dietary indole-3-carbinol (I3C) supplementation96, 97. 
Using this rat model, J.J. Mullins‘ group identified severe albuminuria and renal 
pathohistological changes mimicking DN in human patients when hypertension was 
induced together with STZ-diabetes. However, it took 7 months of diabetic conditions 
to develop these alterations. Importantly, they have also shown that none of the 
genes that were upregulated in human DN were induced through diabetes alone in 
rats whereas 21% were upregulated in the hypertensive rats and 42% in the diabetic 
and hypertensive rats98.  
Rats suffering from diabetes and hypertension for 28 weeks generally have high 
mortality and morbidity, and show aging-related symptoms, which complicate studies 
on these rats. A similar problem also persists in obese murine models. Although they 
develop significant renal failure and glomerular impairments, either disease 
progression takes too much time (28 weeks to 40 weeks) or it is difficult to 
understand the real reason of the disease since obesity models have both 
hypertension and hyperglycemia. Due to these problems, a novel rat model to study 
diabetic nephropathy is urgently needed. 
1.4.5 The TGR Neph-hAT1R rat 
Another model targeting elements of the RAAS is a transgenic rat which specifically 
overexpresses the AT1R in podocytes, which was developed in 2004 by our research 
group39. As a result, these rats develop albuminuria and FSGS in the absence of 
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HBP. The disease starts to develop when rats are more than 16 weeks old and 
progress slowly. 
1.5 Expansion microscopy 
Biopsy samples obtained from patient kidneys are mostly stained with hematoxylin 
and eosin (H&E), Periodic acid–Schiff (PAS) and Heidenhain's AZAN trichrome stain 
(AZAN) depending on the suspected disease. These samples are then examined 
under a light microscope to identify the disease or to evaluate the disease 
progression. Pathologists can detect fibrosis, FSGS99, glomerular hyalinosis99, 
mesangial expansion99, glomerular adhesion100, tubulopathy101 and more using 
conventional light microscopy. However, the resolution of light microscopy is limited 
by the diffraction limit of light which varies between 180 – 250 nm, depending on the 
wavelength of the light used, the refractive index of the immersion media and the 
focusing angle of the objective. However, important markers for the diagnosis of 
glomerular diseases such as GBM thickening and FPE are separated by less than 
100 nm, making them impossible to resolve using traditional light microscopy. This is 
why electron microscopy (EM), which provides a resolution 10- to 100-fold better, 
was required102, 103. The recently developed method of super-resolution 
microscopy104 achieves a resolution beyond the diffraction limit of light and 
overcomes some of the drawbacks of EM, like the limited ability to study the 
distribution of specific proteins using antibody labelling105, 106 and the super-thin 
<100nm sections that limit high-resolution volumetric information105, 106. Despite of 
this, super-resolution microscopy is still limited by a working distance of between 10-
20µm. Moreover, both techniques, EM and super-resolution microscopy, require 
sophisticated instruments and are technically demanding. The necessity for 
expensive and highly specific fluorophore-conjugated antibodies limits the use of 
super-resolution microscopy. 
In 2015, the Boyden group established a method called expansion microscopy 
(ExM)107, which allows large-volume-super-resolution imaging using confocal 
microscopy. Unlike other super-resolution imaging techniques, ExM achieves super-
resolution beyond the diffraction limit by physically expanding the tissue sample in a 
swellable hydrogel, which is placed into water to expand 4 to 4.5 fold isotropically, 
and thereby increasing the effective resolution by the same factor.  
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Today, multiple variants and applications of the ExM technique exist, such as 
Protein-retention ExM, Magnified analysis of the proteome (MAP), Expansion 
fluorescent in-situ hybridization (ExFISH), iterative expansion Microscopy (iExM). The 
main difference among the methods is how the target protein or structure is 
labeled108-113.  
Altogether, the main advantages of ExM are;  
1. Conventional antibodies can be used to label a protein of interest110, 
whereas labeling is still an issue in electron microscopy, and specific antibodies are 
very expensive for super-resolution microscopy.  
2. Conventional microscopes such as confocal and fluorescent microscopes 
can be used with no modification  
3. ExM does not have any limitations on free working distance allowing super-
resolution imaging in 3D of large-volume samples, while electron microscopy is 
restricted by super-thin samples with a maximum of 100nm and super-resolution 
microscopy limits the working distance to between 10 and 20μm.  
The principal of ExM is similar to the optical clearing technique CLARITY114, originally 
developed by the Deisseroth group in 2013, which renders tissue transparent. Thus, 
the light scattering properties of biological tissues are avoided, and by using confocal 
microscopy, the imaging depth can be increased to study large three-dimensional 
structures. Scattering of light in biological samples occurs due to non-homogenous 
refraction indexes in tissues. The basic method for ExM is the immersion of the tissue 
in a solution containing paraformaldehyde (PFA) for fixation of amino groups, and 
acrylamide monomers, which will in turn bind to the PFA molecules and form the gel. 
In addition, sodium acrylate is added, which absorbs water when polymerized and 
swells. The acrylamide is then polymerized, anchoring the proteins in a firm gel that 
keeps the integrity of the sample. The lipids are removed by SDS, and the proteins 
are denatured by heating. By removing lipids, the RI differences between proteins 
and lipids disappear.   
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1.6 The aim of the study 
There is a lack of animal models mimicking the structural alterations typically seen in 
human glomerular diseases. The resistance to diabetic nephropathy in rodent models 
might partly be explained by the lack of hypertension as a contributing factor or 
second hit.  
In humans, DN affects only 30% of diabetic patients and is often associated with 
hypertension or obesity as contributing co-factors115, 116. A hallmark of chronic kidney 
diseases caused by diabetes and hypertension is the leakage of the GFB leading to 
albuminuria and glomerulosclerosis. A key component of the GFB is the podocyte, 
which is directly regulated by Ang II via its AT1R. Nanoscale evaluation of podocyte 
FPs required electron microscopy since the physical diffraction limit of optical 
microscopes prevents high-resolution imaging.   
Thus, this study had the following aims:  
1. Develop a rat model, which mimics glomerular lesions in human DN.  
2. Compare the effects of HBP, DN and synergistic action of HBP and DN on the 
kidney. 
3. Study the role of AT1R signaling in podocytes in these diseases  
4. Develop an ExM method for nanoscale evaluation of the podocyte FPs to 
quantify the degree of FPE in these diseases 
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2 MATERIAL AND METHODS 
2.1 Materials 
Materials are the machine, device, software, chemicals, solutions and other 
consumables used during the experiment. 
2.1.1 Equipment 
Table 1:  Devices and equipment used to complete this research. 
 
 
 
 
 
Name of product Company Catolog Number 
Multi-Functional Precision Balances A&D Medical APOLLO GF-A 
Accu-Chek Compact Plus Roche Inc. Accu-Chek Compact 
Plus 
Sphygmomanometer S-2 Hugo Sachs 
Elektronik, Germany 
Ser. No. 9003 
USB-Device Mannheim Pharma & 
Diagnostics GmbH 
NIC USB device 
(UDxxx) 
Semi-enclosed Benchtop Tissue 
Processor 
Leica TP1020 
HistoCore Arcadia H - Heated 
Paraffin Embedding Station 
Leica 14039357258 
Autostainer XL Leica ST5010 
HistoCore MULTICUT - Semi-
Automated Rotary Microtome 
Leica 149MULTI0C1 
Cryostat Leica CM3050 S 
Vibrating blade microtome Leica VT1200 S 
Sp8 Confocal Microscope Leica Leica TCS SP8 
Axio Scan.Z1 Slide Scanner ZEISS Axio Scan.Z1 
Dyad Peltier Thermal Cycler Bio-Rad PTC-220 
Gel Electrophoresis System Thermo Scientific OW-D2BP 
Gel Imager Intas GEL iX20 Imager 
Windows Version 
Cobas c 311 analyzer Roche Diagnostics 
International Ltd. 
RS-232C 
Infinite® 200 PRO Plate Reader Tecan Trading AG Infinite M200 
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2.1.2 Software for analysis 
Transcutaneous GFR Measurement: 
• MPD Studio Ver. RC14 (MediBeacon Inc.) 
• MPD Lab Ver. 1.0B (MediBeacon Inc.) 
Image Processing: 
• Leica Application Suite X (LAS X) (Leica Microsystems Inc.) 
• Zen Blue Edition (Carl Zeiss Microscopy GmbH) 
Statistics: 
• JMP 13 (JMP Inc.) 
• Microsoft Excel 2010 (Microsoft Inc.) 
 
2.1.3 Chemicals and commercial kits 
Table 2: Chemicals, commercial solutions and kits used in the experiment. 
 
Name of product Company Catolog Number 
Sodium hydroxide (NaOH) Merck 106462 
Ethylenedinitrilotetraacetic acid (EDTA) Sigma-Aldrich 1233508 USP 
Tris base Sigma-Aldrich TRIS-RO Roche 
Hydrochloric Acid (HCl) 37% Sigma-Aldrich 258148-2.5L 
Platinum™ Hot Start PCR Master Mix 
(2X) 
Invitrogen 13000012 
Nuclease-Free Water (not DEPC-
Treated) 
Invitrogen AM9932 
UltraPure™ Agarose Invitrogen 16500100 
Acetic acid (glacial) 100% Merck 1000631000 
Xylene Cyanol FF Sigma-Aldrich X4126-10G 
Bromophenol Blue Sigma-Aldrich B0126-25G 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich 862010 
Glycerol Sigma-Aldrich G9012-500ML 
UltraPure™ Ethidium Bromide, 10 
mg/mL 
Invitrogen 15585011 
Streptozocin (STZ) Sigma-Aldrich S0130-5G 
Water for injections (5ml) Braun PL 03551/0077 
ROMPUN® 2 % Bayer 6770081 
Ketamin ® 2 % Bayer 2645528 
Pellet food I3C FUJIFILM Wako 
Chemicals 
S5904-P012 
Paraformaldehyde (PFA) Sigma-Aldrich 158127-3KG 
NaCl Sigma-Aldrich S7653-1KG 
Material and Methods 
 
25 
 
Name of product Company Catolog Number 
KCl Sigma-Aldrich P9333-500G 
Na2HPO4 Sigma-Aldrich NIST2186II 
KH2PO4 Sigma-Aldrich NIST200B 
Sodium Hydroxide 1N (NaOH) SAFC 59223C 
Hydrochloric acid 1N (HCl) Sigma-Aldrich H9892-1L 
Sucrose Sigma-Aldrich S0389-1KG 
2-Methylbutane ( Isopentane) Sigma-Aldrich M32631-1L 
Liquid Nitrogen   
40% Acrylamide Solution BIO-RAD 1610140 
2% Bis Solution BIO-RAD 1610142 
16% Paraformaldehyde Solution Thermo Fisher Scientific 15710 
Sodium acrylate 97% Sigma-Aldrich 408220-100G 
2,2'-Azobis[2-(2-imidazolin-2-
yl)propane]dihydrochloride (VA-044) 
FUJIFILM Wako 
Chemicals 
925-41020 - VA-
044 
Bovine Serum Albumin (BSA) Sigma-Aldrich F9665-50ML 
4-(1,1,3,3-Tetramethylbutyl)phenyl-
polyethylene glycol (Triton™ X-100) 
Sigma-Aldrich X100-500ML 
m-Xylene ≥99% (Xylol) Sigma-Aldrich 296325-1L 
Ethanol Merck 1009832511 
Hematoxylin solution Merck 1051741000 
Eosin Y Sigma-Aldrich E4009-25G 
Periodic acid 
ACS reagent, 99% 
Sigma-Aldrich 375810-100G 
Schiff’s reagent Sigma-Aldrich 3952016-500ML 
Hematoxylin Solution, Mayer’s Sigma-Aldrich MHS16-500ML 
Azocarmine G Sigma-Aldrich A1091-25G 
Aniline ≥99.5% Sigma-Aldrich 242284-100ML 
Tungstophosphoric acid hydrate Merck 100582.01 
Aniline Blue diammonium salt Sigma-Aldrich 415049-25G 
Orange G Sigma-Aldrich O7252-25G 
Tissue freezing medium Leica 14020108926 
ProLong™ Diamond Antifade Mountant Invitrogen P36970 
 
 
2.1.4 Primers for genotyping 
The TGRNeph-hAT1R were genotyped using the following primers: 
Forward primer: 5'-GAA GGA ACC TTA CTT CTG TGG-3' 
Reverse primer: 5'-TCT TGT ATA GCA GTG CAG C-3’ 
 
The Cyp1a1ren2 rats were not genotyped since the transgene was integrated in the 
Y-chromosome so that all male rats of this line harbored the transgene.  
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2.1.5 Antibodies 
Table 3: Primary and secondary antibodies used in this research. 
Name Species Raised / 
Raised-Against 
Use Company Cat.No. Excitation 
Wavelength 
Podocin Rabbit 1st Sigma p0372-
200ul 
X 
Collagen 
4 
Rabbit 1st Progen 10760 X 
Nephrin Guinea Pig 1st Progen GP-N2 X 
VDAC Mouse 1st Abcam ab14734 X 
Alexa 546 Chicken Anti-
Rabbit 
2nd Life 
Technologies 
A10040 546 
Alexa 647 Chicken Anti-
Mouse 
2nd Invitrogen A-21463 647 
Alexa 594 Chicken Anti-
Rabbit 
2nd Life 
Technologies 
A-21442 594 
Alexa 633 Goat Anti-Rabbit 2nd Life 
Technologies 
A-21070 633 
Alexa 594 Donkey Anti-Goat 2nd Life 
Technologies 
A11058 594 
2.1.6 Solutions prepared 
Acetic Alcohol 
 10ml acetic acid 
 Make up to 1L with 96% ethanol 
Aniline Alcohol 
 1ml aniline oil 
 Make up to 1L with 96% ethanol 
Aniline Blue-Orange G solution 
 5g aniline blue 
 20g orange G 
 800ml ddH2O 
 80ml acetic acid 
 Make up to 1L with ddH2O 
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0.1% Azocarmine G 
 1g azocarmine G 
 800ml ddH2O 
 Heat for 1 hour then cool to room temperature 
 6ml glacial acetic acid 
 Make up to 1L with ddH2O, filter 
Blocking Solution (IHC) 
 1g BSA 
 50µl Triton X-100 
 Make up to 50ml with PBS 
0.2M Cacodylate buffer 
 42.8g Sodium Cacodylate 
 Fill up to 1L with ddH2O 
 pH to 7.4 with either 0.2M HCl or 0.2M NaOH 
10x DNA loading buffer 
 4g Sucrose 
 2.5mg Bromophenol Blue 
 10ml TE buffer 
 
0.5M EDTA (pH 8.0) 
 186.1g EDTA 
 800ml ddH2O 
 pH to 8.0 with NaOH 
 Make up to 1L with ddH2O, autoclave 
Karnovsky Fixative 
 2g paraformaldehyde 
 Dissolve in 25ml ddH2O by adding 2-3 drops of NaOH, heating to 70°C and 
stirring 
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 Cool to room temperature 
 5ml 25% glutaraldehyde 
 Make up to 100ml with 0.2M cacodylate buffer 
  pH to 7.4 with HCl 
4% Paraformaldehyde 
 40g paraformaldehyde 
 100ml 10x PBS 
 700ml ddH2O 
 Add 3-4 drops of concentrated NaOH 
 Heat with stirring until dissolved 
 pH to 7.4 with NaOH 
 Fill up to 1L with ddH2O 
 Filter and store at -20°C 
10x Phosphate Buffered Saline (PBS) 
 80g NaCl 
 2g KCl 
 2.4g KH2PO4 
 14.4g Na2HPO4 
 Add 800ml ddH2O 
 pH to 7.4 with HCl 
 Fill up to 1L with ddH2O, autoclave 
1x Phosphate Buffered Saline (PBS) 
 100ml 10x PBS 
 Fill up to 1L, autoclave 
Phosphotungstic acid 
 50g phosphotungstic acid hydrate 
 Make up to 1L with ddH2O 
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Proteinase K 
 100mg proteinase K 
 10ml ddH2O, aliquot and store at -20°C 
RNase A 
 100mg RNase A 
 10ml 10mM sodium acetate 
 Heat to 100°C for 15 minutes, cool to room temperature 
 Adjust the pH to 7.4 with 1M Tris-HCl 
 Aliquot and store at -20°C 
18% Sucrose 
 90g Sucrose 
 50ml 10x PBS 
 Make up to 450ml with ddH2O 
50x TAE Buffer 
 242g Trizma base 
 57.5ml acetic acid 
 100ml 0.5M EDTA (pH8.0) 
 Make up to 800ml with ddH2O 
 pH to 8.5 with concentrated NaOH  
 Make up to 1L with ddH2O, autoclave 
Tail Buffer 
 50ml 1M Tris-HCl (ph 8.0) 
 200ml 0.5M EDTA 
 20ml 5M NaCl 
 100ml 10% SDS 
 Make up to 1L with ddH2O, autoclave 
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1M Tris-HCl 
 121g Trizma base 
 800ml ddH2O 
 Use concentrated HCl to get to desired pH 
 Make up to 1L with ddH2O, autoclave 
 
2.2 METHODS 
2.2.1 Animals 
All animal studies were conducted in accordance with federal and local laws and 
were approved by the Regierungspräsidium Karlsruhe, Land Baden-Württemberg 
(G77/17, G76/18).  
The animals were bred and housed in our own animal facility at the Medical Faculty 
Mannheim. The animal experiments were performed on three rat lines; ZSF-1 rats, 
Sprague Dawley rats and crosses of TGRNeph-hAT1R and TGRCyp1a1Ren2 rats. 
Male ZSF-1 (Leprfa/Leprcp/Crl) ob/ob rats and their lean controls were purchased from 
Charles River Company, and Sprague Dawley rats were purchased from Janvier. 
The ZSF-1 rat is an F1 hybrid from crossing lean female fatty diabetic rats (ZDF; +/fa) 
with lean male spontaneously hypertensive heart failure rats (SHHF/Mcc-facp; 
+/fa, +/+)117. For the eperiments 8-10 rats/group were used if not other indicated. 
 The TGRNeph-hAT1R rat, which specifically overexpresses the AT1R in podocytes, 
was developed in our own group39 and the TGRCyp1a1Ren2 rat, which carries an 
I3C dietary inducible transgenic renin gene incorporated in the Y-chromosome, was 
developed by Prof. John Mullins, Edinburgh94, 97. Two-month-old male Sprague 
Dawley rats were rendered diabetic by using a single dose of STZ (35 mg/kg, i.v.). 
Untreated rats served as controls. After 10 weeks and 7 months, urine was collected 
for 24 hours using metabolic cages with water and food access ad libitum, after which 
blood was taken.  
ZSF1 rats spontaneously develop diabetes. 10 ob/ob and 8 control rats were used in 
the experiment. In ZSF1 rats, renal function, glucose status and blood pressure were 
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determined between the ages of 8 weeks and 40 weeks at monthly intervals. Urine 
samples were collected at 8, 12, 13, 16, 22, 27, 30, 33, 37 and 40 weeks of age.  
In order to compare the effects of hypertension with the synergistic effects of 
hyperglycemia and hypertension on the same genetic background and to study the 
role of AT1R signaling in these disease conditions, we crossbred female 
heterozygous TGRNeph-hAT1R rats with male TGRCyp1a1Ren2 rats to obtain male 
transgenic Cyp1a1Ren2 rats either carrying (TGR) or not carrying (Wild) the Neph-
hAT1R transgene in addition. Renin transgene expression was induced by the 
0.125% I3C supplementation in the food. Blood pressure increased within 24 hours. 
Male rats not treated by I3C were normotensive. Diabetes was induced by a single 
dose of STZ (60 mg/kg, i.p.). This breeding procedure resulted in 50% Neph-hAT1-
TG/Cyp1A1Ren2a-TG (TGR) and Neph-hAT1-wt/CypARen2a-TG male rats (Wild) 
[Figure 5].  
All the rats used in this experiment have been housed in a social cage (3-4 rats for 
per cage). Cages were cleaned twice per week for controls (CTRL) and HBP rats 
while the cages that held diabetic rats were cleaned 3-4 times per week due to 
excessive urine production. Autoclaved sawdust and some paper were used as 
bedding material, and some enrichment (nesting material, wood particles and some 
piece of paper) was provided to enhance the social activities of the rats. Pellet food 
and water was provided ad libitum, and all cages were controlled daily by animal 
house staff. The rooms housing animals were kept at 22°C ± 1°C temperature and 60 
± 10 % of relative humidity, with a 12 hours alternate light and dark cycle and 100 % 
fresh air exchange.  
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Figure 5: Mating schema to create double transgenic male rats. A- Male rat which carries inducible 
renin gene (Cyp1A1Ren2a) and the female rat which carries Neph-hAT1R transgene (Neph-hAT1 
TG/WT).  B- Female offspring which do not carry the CypA1Ren2a transgene, but they are either 
Neph-hAT1 (TG) or Neph-hAT1 (WT) for AT1 R transgene. C- Male offspring which all carries the 
CypA1Ren2a transgene, but they are either Neph-hAT1 (TG) or Neph-hAT1 (WT) for AT1R transgene. 
2.2.2 DNA isolation and genotyping 
DNA samples for genotyping were extracted from the tissue samples collected during 
ear markings. Samples were placed into PCR tubes and incubated in 75µl of 25mM 
NaOH and 0.2 mM EDTA solution for 1 hour at 98°C. Then, samples were cooled on 
ice for 15 minutes after which 75µl of 40mM Tris-HCl (pH 5.5) was added. Samples 
were then centrifuged at 4000 g for 3 minutes. 100µl aliquots were transferred to new 
PCR tubes, and 2µl of each aliquot was used for genotyping by PCR. 
After the PCR reaction, samples were run on a 1.5% agarose gel at 100V for 25 
minutes at room temperature. The gel was then imaged by UV light to record positive 
(Transgenic, or TGR) and negative (Wild Type, or WT) rats. 
2.2.3 Design of HBP and diabetes experiments  
Male Neph-hAT1-tg/Cyp1A1Ren2a-tg (TGR) and Neph-hAT1-wt/CypARen2a-tg 
(Wild) 6 weeks old rats were divided into six experimental groups (CTRL-TGR, 
CTRL-Wild, HBP-TGR, HBP-Wild, D-HBP-TGR, D-HBP-TGR). In D-HBP rats, 
diabetes was induced at the age of 6 weeks by intraperitoneal injection of 60mg/kg 
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STZ. After two weeks, D-HBP and HBP rats received pellet food supplemented with 
0,125%   I3C until the end of the experiment to induce HBP. Control rats were fed 
with standard pellet food. Finally, the animal experiments were terminated after 8 
weeks when the rats were 14 weeks old [Figure 6]. 
 
Figure 6: Demonstration of the experimental timeline. Control rats were not treated. HBP rats were 
fed by pellet food, which contains 0,125% Indole-3-Carbinol (I3C) 2 weeks after the beginning. D-HBP 
rats were intraperitoneally injected with 60mg/kg of streptozocin at the beginning of the experiment, 
then fed by pellet food which contains 0,125% Indiole-3-Carbinol (I3C) 2 weeks after. All rats were 
sacrificed 8 weeks later. 
2.2.4 Health monitoring 
Blood glucose concentration, blood pressure, body weight and rat grimace scale 
were monitored during the experiment to evaluate the health condition of the rats118. 
Blood pressure was measured using a tail-cuff once per week while blood glucose 
concentration and body weights were measured twice per week. The appearance 
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and social behavior of the rats were observed twice per week and evaluated 
according to the rat grimace scale. 
2.2.5 Induction of diabetes 
Diabetes was induced by administrating of a single intraperitoneal dose of STZ (60 
mg/kg). Bodyweight, blood glucose level and behavior of the rats were monitored 
until the end of the experiment. 
2.2.6 Induction of hypertension by Indole-3-carbinol 
Hypertension was induced by dietary application of pellet food supplemented by 
0.125% I3C (cat.no. S5904-P012, ssniff Spezialdiaten GmbH), which induced 
transgenic renin expression in the Cyp1A1Ren2a rat model as previously 
described211. Blood pressure was then monitored by tail-cuff plethysmography twice 
per week. 
2.2.7 Metabolic cages 
All experimental rats (CTRL, HBP and D-HBP) were placed in metabolic cages for 24 
hours to collect urine samples and to evaluate water and food consumption. Powder 
food and water were supplied ad libitum. All rats in the metabolic cages were 
monitored every 8 hours for health. Blood plasma was taken in parallel. Clinical data 
from plasma and urine were determined to evaluate renal function, calculate GFR 
and the degree of proteinuria and albuminuria for each rat. 
2.2.8 Transcutaneous measurement of the GFR 
The GFR was measured transcutaneously using a GFR device in four rats/group in 
the second (2 weeks after diabetes induction and just before HBP induction) and 
sixth weeks (4 weeks after induction of hypertension) of the experiment [Figure 7]. 
The rats were anesthetized by isoflurane vapor. Hairs were removed using a shaving 
machine followed by incubation with hair loss cream (Cat.no. 86725 
(867250860115), Nivea) for 3 minutes to get rid of fine hairs. Hairless skin was 
washed by distilled water and the rat was incubated for 10 minutes at 37°C. After the 
determination of the body weight, the transcutaneous GFR device was placed on the 
naked skin. FITC-Sinistrin (3mg/100g) was injected intravenously in the tail. The rat 
was then placed into a fresh cage and received pellet food and some enrichments 
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but no water. The GFR was measured for 2 hours. The data were saved in CVS 
format and then processed by MPD Studio (Ver. RC14, MediBeacon Inc.) to calculate 
the half-life. 
 
Figure 7: Setup for transcutaneous GFR measurement. A- the components of transcutaneous GFR 
measurement device; 1- two-sided tape with a small square hole, 2- battery and 3- device. B- 
Assembly of the device on the two-sided tape. C- Prepared FITC-Sinistrin before injection. D- Shaved 
rat after anaesthetization. E- The assembled device stuck over the shaved area before FITC-Sinistrin 
injection. F- The rat immediately after wake up. G- The rat urinated after a while. 
 
2.2.9 Creatinine clearance as an estimate of the GFR 
The creatinine clearance was calculated using the following formula.  
𝐺𝐹𝑅 =
[𝑈𝐶𝑟 ∗ 𝑉]
𝑆𝐶𝑟
∗
1000
1440
 
𝐺𝐹𝑅 = 𝑚𝑙/𝑚𝑖𝑛 
** Creatine clearance tends to exceed the correct GFR by 10 to 20 percentage. 
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UCr is urinary creatine concentration, V is urine produced in 24 hours, SCr is serum 
creatine concentration. 
2.2.10 Termination of the experiment and eample collection 
The experiments were terminated at the age of 14 weeks, namely 8 weeks after STZ 
injection and 6 weeks after induction of hypertension. Rats were anesthetized with 
5mg/kg of Ketamine ® 2% and 100mg/kg of ROMPUN® 2 % (xylazine based drug) 
mixture. After the rat became unresponsive to the withdrawal reflex, the dissection 
procedure was started. The right kidney was collected before perfusion, placed into a 
2ml tube as pieces and immediately frozen with liquid nitrogen. Then, the rat was 
sacrificed by retrograde total body perfusion with the fixative 2 % paraformaldehyde 
(PFA) in PBS, pH 7.4, containing 0.05% glutaraldehyde (GDA) for 3 min at a 
pressure of 220 mmHg as previously described119. Kidney, heart and liver were 
harvested for light microscopy. The perfused left kidney was divided into five pieces 
using a matrice. One thin middle part for paraffin embedding and a thick middle part 
for expansion microscopy were placed into 4% PFA, and incubated overnight at 4°C. 
Other thin slices from the mid parts were placed into karnovsky fixative for electron 
microscopy. The remaining two end pieces were saturated overnight in 18% Sucrose 
in PBS and then frozen in isopentane at -30°C followed by liquid nitrogen.  
2.2.11 Post fixation and paraffinization 
Fixed samples were placed into plastic cassets for post-fixation and paraffinization 
procedures. Samples were then incubated in 4% Formalin for 1.5 hour twice and 
followed by incubation of 70% ethanol, 80% ethanol, 96% ethanol, 99% ethanol 
twice, 100% xylol twice and liquid paraffin (60°C) 3 times for 1.5 hours each. 
Samples were then embedded into paraffin blocks and left to cool. 
2.2.12 Clinical parameters 
All the physiological parameters obtained from blood plasma and urine were 
measured by the core facility of the ZMF by the use of a cobas C 311 analyzer 
(Roche Diagnostics) except urinary albumin data. This was measured by the core 
facility using an albumin elisa kit (peroxidase-conjugated rabbit IgG antibody, 
Cat.no.55775, Abcam) and an elisa reader (Infinite® 200 PRO Plate Reader, Tecan 
Trading AG). 
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2.2.13 Histological staining and sample examination  
2.2.13.1 Hematoxylin and Eosin staining 
Hematoxylin and eosin stain (abbreviated as H&E stain) is one of the principal tissue 
staining methods used in histology. The aim of the staining is to make tissue 
sections, which is naturally transparent, visible and distinguishable under the light 
microscope. H&E stain consists of two histological stains: hematoxylin and eosin. 
The hematoxylin (cationic dye) stains cell nuclei blue, and eosin (anionic dye) stains 
the extracellular matrix and cytoplasm pink. 
To stain the samples with H&E, 3 µm sections were cut by microtome and placed on 
slides und were dried at 60°C for 1 hour then cooled down for 10 minutes at room 
temperature. The sections were incubated 3 times in xylene for 5 minutes for 
deparaffinization, and then the samples were incubated in the following series of 
ethanol concentrations- 100%, 96%, 80%, 70% and ddH2O for 2 minutes each. 
Thereafter, they were stained by hematoxylin for 4 minutes, washed with tap water 
for 10 minutes, and incubated for 2 minutes in eosin solution. The sections were 
dehydrated by washing in ddH2O for 1 minute, and then the samples were incubated 
in the following series of ethanol solutions- 70%, 80%, 96% and 3 times in 100% 
ethanol for 2 minutes. Finally, samples were incubated 3 times in xylene for 5 
minutes each. Stained samples were mounted with polylysine. 
2.2.13.2 Periodic acid–Schiff staining 
Periodic acid–Schiff (commonly known as PAS) is a staining technique which is used 
to detect polysaccharides, mucosubstances such as glycoproteins and glycolipids. 
To perform this staining, 3 µm sections cut by microtome and placed on glass were 
incubated at 60°C for 1 hour then cooled down for 10 minutes at room temperature.  
The sections were incubated 3 times in xylene for 5 minutes for deparaffinization, and 
then the samples were incubated in the following series of ethanol concentrations- 
100%, 96%, 80%, 70% and ddH2O for 2 minutes each. Thereafter, they were 
incubated in 0.5% periodic acid solution for 5 minutes, washed in ddH2O for 1 
minute, and then incubated in Schiff reagent for 15 minutes. Sections were washed 
under running tap water for 5 minutes, and then dehydrated in the following series of 
ethanol concentrations- 70%, 80%, 96% and 3 times in 100% ethanol for 2 minutes 
Material and Methods 
 
38 
 
each. Finally, the samples were incubated 3 times in xylene for 5 minutes each. 
Stained samples were then mounted with polylysine. 
2.2.13.3 Heidenhain‘s AZAN stain 
Heidenhain's stain, or Heidenhain's AZAN trichrome stain, is a staining methods in 
which three anionic dyes (azocarmine G, aniline blue and orange G) are used in 
cooperation with phosphotungstic acid (PTA). Azocarmine G stains nuclei, 
erythrocytes, fibrin, fibrinoid, acidophilic cytoplasm and epithelial hyalin red. Aniline 
blue and orange G counterstains collagen fibers, basophilic cytoplasm and mucus 
blue and orange. 
3 µm sections were incubated at 60°C for 1 hour then cooled down for 10 minutes at 
room temperature. The sections were incubated 3 times in xylene for 5 minutes for 
deparaffinization, and then the samples were incubated in the following series of 
ethanol concentrations- 100%, 96%, 80%, 70% and ddH2O for 2 minutes each. Then 
the samples ware washed in in 0.1% azocarmine G solution for 20 minutes at 56°C 
followed by a wash in running tap water for 2 minutes. The intensity of the staining 
was controlled by 3 short (10 seconds to 1 minute) washing steps with aniline alcohol 
until the staining of the nucleus and cytoplasm were distinguishable. After that, the 
reaction was stopped by the acetic acid solution. The collagen content in the sample 
was then stained by incubating in 5% phosphotungstic acid for 20 minutes, washed 
in running tap water, and lastly incubated in aniline blue-orange G solution. The 
samples were dehydrated by ddH2O wash, and cleared by washing twice in 96% 
ethanol and then incubated twice in 100% ethanol for 2 minutes and twice in xylene 
for 5 minutes. Stained samples were then mounted by polylysine. 
2.2.13.4 Determination of the damage index 
The damage indexes were calculated using AZAN stained tissue section. We 
designated five categories of glomerular damage G0 – G5, whereby G0 
characterized healthy glomeruli and G5 sclerotic glomeruli. An average of 180 
glomeruli per rat were evaluated. 
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2.2.13.5 Electron microscopy  
The preparation of the samples and electron microscopy was performed by Prof. 
Gröne, DKFZ and Prof. Kriz, Medical Faculty Mannheim, University Heidelberg using 
standard techniques.  
2.2.13.6 High-Resolution light microscopy 
Thin-section light microscopy was performed by Prof. Kriz, Medical Faculty 
Mannheim, University Heidelberg, as previously described14. With a diamond knife, 
0.5 µm thick sections were obtained and stained with methylene blue and used for 
high-resolution light microscopy.  
2.2.14 Expansion microscopy and immunohistochemistry  
2.2.14.1 Expansion microscopy for kidney samples 
Kidney samples were incubated overnight in 4% PFA thereafter placed into 
Amplification Hydrogel Solution (AHS) in a 50 ml falcon tube wrapped with foil and 
incubated on a shaker for 2-3 days at 4°C (AHS: tissue ratio = 10:1). After that, 
samples were placed into a 6 well plate filled with AHS. Then the solution was covert 
by mineral oil to avoid oxygen in the air. The plate was incubated in a humidified 
chamber at 37°C for 2 hours polymerization. After the polymerization step, the tissue 
containing gel was trimmed to minimize volume, using a sharp razor blade. Next the 
gel was washed for 2 hours at room temperature in 1xPBS with shaking. The 
samples were further processed by cutting 500 µm slices using a vibratome and were 
then placed into a 24 well plate with 1xPBS.  All the slices were then stored at 4°C in 
1x PBS. Clearing of the tissue was achieved by removing the lipids due to incubation 
of the samples in 6 well plates in a wet chamber in denaturation solution with SDS for 
12 hours at 70 °C, followed by further 12 hours at 95°C (1mm thick tissue 2x 24hr). 
The denaturation step should not be too short; otherwise, it blunts the expansion, and 
not too long; since then, the tissue becomes too fragile. Thereafter the samples were 
washed 2-4 hours in 1x PBST with shaking at room temperature to eliminate 
denaturation solution. After this step, denatured samples were transparent and 
fragile. These samples can be kept for 6 months at 4°C for long term storage. 
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2.2.14.2 Immunohistochemistry for expansion microscopy and imaging 
samples 
Denatured and 1x PBS washed samples were cut into small pieces, and accordingly 
placed into 24 well plates containing 1 ml of 1x PBS in each well. Then, 1x PBS was 
replaced with 500 μl blocking buffer (2% BSA in 1x PBS with 1% Triton X-100). 
Thereafter, samples were incubated overnight at 37°C in a humidified chamber. The 
blocking buffer was then replaced with 350 μl of primary antibody solution, which 
contained blocking buffer and primary antibody in a ratio indicated on the table (see 
2.1.5) and incubated overnight. Later on, samples were washed 3 times for 10 
minutes each. Then, the samples 350μl of secondary antibody solution was added 
and incubated overnight, and then washed 3 times for 20 minutes each. Samples 
were then ready to proceed with the first imaging at the confocal microscope.  
For expansion, the PBS needs to be carefully removed and the sample is placed into 
a 10 ml plate with an excess of deionized water for 1-2 days at room temperature. 
The water is changed 3-4 times during this period. Then the samples were again 
imaged at the confocal microscope. The expanded tissue consists of more than 90% 
of water, thus it is transparent and the RI index matches to water (RI 1.33). 
Autofluorescence is strongly reduced. For imaging, the gels were placed into a 3 mm 
plate with a glass bottom and immobilized with 2% low melt agarose in water to 
prevent movement during imaging. For imaging 10x, 20x, and 63x water immersion 
objectives were used. Thereafter, the tissues were shrunken by placing it into 1xPBS 
for further storage. For repeated immunohistochemistry, the shrunken sample is 
destained by incubation in denaturation solution 6-16 hr at 70°C, thereafter wash 3x 
in PBST each for 2hr at 37°C. Then the next immunohistochemistry is started as 
described above. 
2.2.14.3 Expansion factor and distortion 
In tissue expansion technique for microscopy, one of the biggest challenge is to 
evaluate the expansion factor. To this end, we compared the maximal longitudinal 
and transverse glomerular diameters/glomerulus and measured 50 glomeruli/rat from 
both, non-expanded frozen H&E stained tissue and expanded tissue from the same 
kidney, which was  podocin stained. Then for each kidney the mean values for both, 
non-expanded frozen tissue and expanded tissue samples, were calculated. The 
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ratio between the mean of expanded glomeruli and the mean of the non-expanded 
glomeruli was calculated as the expansion factor for an individual rat. Morphometric 
measurements in expanded tissues (podocyte FP width’s) were then divided through 
the individual expansion factor. The ratios between the longitudinal and transverse 
glomerular diameters were calculated for each glomerulus to determine the distortion. 
2.2.14.4 Structured Illumination Microscopy (SIM) 
Structured Illumination Microscopy (SIM) analysis of the podocyte slit membrane 
density was performed by Prof. N. Endlich, University Greifswald, Fa. Nipoka using 
previously described technique106. For the quantification of the FP structure they 
developed a software-based approach named Podocyte Exact Morphology 
Measurement Procedure (PEMP) and measured the filtration slit density (FSD), 
which highly correlated inversely with FP width.     
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3 RESULTS 
3.1 Kidney pathologies in classical rat models of diabetes 
3.1.1 Effect of STZ induced diabetes on the rat kidney 
Previous experiments in our research group demonstrated that STZ-induced diabetes 
in Sprague Dawley rats only causes minor alterations in the kidney, even after 7 
months of diabetes. Table 4 shows significantly altered clinical data from the urine 
and plasma of diabetic rats, 10 weeks and 7 months after the induction of diabetes, 
relative to age-matched controls. Diabetic rats showed features typical of type-1 
diabetes, including diuresis and increased water and food consumption. The urinary 
albumin excretion, an early indicator of diabetic nephropathy, was slightly increased 
10 weeks after diabetes induction (4.5 mg/24hr vs. 0,45mg/24hr in controls) and 
progressed only moderately during a 7 month period of diabetes (7.48 vs. 
0.53mg/24hr in controls). The renal histology did not reveal any pathological changes 
in kidneys morphology [Figure 8], although metabolic alterations in tubular epithelial 
cells occurred already 4 weeks after induction of diabetes. Periodic acid staining 
(PAS) and oil red staining revealed increased lipid and glycogen deposits within 
tubules suggesting a disturbed cellular metabolism. Moreover, increased proliferation 
was noted, as shown by Ki-67 immunohistochemistry [Figure 9]. Overall, SD rat 
kidneys show resistance to STZ-induced diabetes and only very early signs of DN 
can be induced. 
 
 
 
 
 
 
 
 
 
 
 
Results 
43 
 
 
Table 4: Clinical data from the plasma and urine of Sprague Dawley rats 10 weeks and 7 months, 
respectively, after induction of diabetes (by STZ injection, 35 mg/kg i.v.). Data are mean ± SD; *p<0.05 
vs. control, **p<0.01 vs. control, ***p<0.001 vs. control, n= 5 rats/group. 
 
 10 weeks STZ-diabetes 7 months STZ-diabetes 
Parameter Control Diabetes Control Diabetes 
Urine, ml/24 hr 14.9 ± 4 142 ± 10,7*** 16 ± 5.7 275 ± 26.4*** 
u-glucose, mg/24 hr 4.4 ± 2 131482 ± 393941** 57.1 ± 25.5 194225 ± 38031** 
u-protein, mg/24hr 13 ± 3 13 ± 14 28.2 ± 9.3 30.9 ± 19.6 
u-albumin, mg/24hr 0.45 ± 0.034 4.58 ± 4.59* 0.53 ± 0.022 7.48 ± 5.17* 
p-urea, mg/dl 38.1 ± 10 60.9 ± 9.7* 39.6 ± 0.9 64.0 ± 6.0** 
p-creatinine, mg/dl 0.33 ± 0.014 0.26 ± 0.02** 0.36 ± 0.05 0.23 ± 0.01** 
p-protein, mg/dl 62.5 ± 2.1 54 ± 5.1 65 ± 4.2 57 ± 3.3 
p-glucose, mg/dl 146 ± 1.4 576 ± 6.7*** 136 ± 4.9 745 ± 80*** 
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Figure 8:  Histological evaluation of diabetic and control kidney samples 7 months after diabetes 
induction by STZ in SD rats. There were no visible structural pathohistological changes in the 
glomeruli and tubuli of both control and diabetic samples. However, in diabetic samples, Armanni-
Ebstein lesions, indicating glycogen accumulation, were observed in selective renal epithelial cells. 
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Figure 9: Histological examination of the diabetic and control kidney samples 4 weeks after diabetes 
induction by STZ in SD rats. Periodic acid staining (PAS) stained some tubules in the diabetic kidney 
samples, but not in control (CTRL). Oil droplets were also observed in renal tubules. Furthermore, Ki-
67, a proliferation marker, stained in diabetic kidney samples, especially in tubules, indicating 
increased proliferation in tubular epithelium. * Scale bar is 200μm for each sample. 
 
 
3.1.2 Renal pathologies in the ZSF1 rat, a model for type II diabetes 
Although a number of experimental diabetic mouse and rat models exist, only those 
with additional pathologies like obesity or hypertension, develop severe renal injuries 
that mimic human DN. Moreover, in humans, DN is often associated with 
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hypertension or obesity. In the current thesis, we studied the renal function and 
phenotype of the ZSF-1 rat (ob/ob). The ZSF-1 rat (Leprfa,Leprcp/Crl) is a F1 hybrid 
from crosses between lean fatty diabetic female rats (ZDF; +/fa) and lean 
spontaneously hypertensive heart failure male rats (SHHF/Mcc-facp;+/fa,+/+). The 
ZSF1 rat spontaneously develops Type 2 diabetes, including renal damage modeling 
diabetic nephropathy. However, similar to other spontaneous rodent models with DN, 
hyperglycemia is combined with metabolic syndromes including obesity, cardiac 
failure and hypertension. Lean rats with the same genetic background were used as 
non-diabetic controls studied. Pathophysiological parameters during the progression 
of the disease are shown in Table 5. The rats started to become diabetic, obese and 
hypertensive at the age of 3 months. The urinary albumin excretion started to 
increase at the same age. At the age of 10 months, severe albuminuria with urinary 
excretion of 304 mg albumin/24hr vs. 0.6 mg albumin/24hr in controls was 
manifested.  The loss in renal function correlated with the histological alterations in 
the kidneys consistent with DN, including arteriolar thickening, tubular atrophy, 
interstitial fibrosis and mesangial expansion and sclerosis in the glomeruli of 10 
months old ob/ob rats [Figure 10 and Figure 11]. Renal sections of ob/ob rats and 
their age-matched lean controls were stained with AZAN or PAS and showed severe 
renal damage in the ob/ob rats. In AZAN staining, the connective tissue was stained 
blue, whereas proteins and their intra-tubular casts were stained red. More than 50% 
of glomeruli show severe mesangial proliferation and FSGS.  
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Figure 10: Heidenhain’s AZAN staining of the ZSF1 lean and ob/ob rats’ kidney. Blue arrows show the 
lumen of tubules which is stained red in ob/ob rats’ kidney sample indicating protein casts while no 
staining observed in lean one. Black arrows indicate the adhesion of glomeruli to Bowman’s capsule 
and FSGS which is not observed in lean rats. Grey arrows point out the thickening of Bowman’s 
capsule which is not found in lean rats. White arrows show the accumulation of connective tissue 
fibers in ob/ob rat kidney. *Proteins are stained as red/violet, and connective tissue fibers are stained 
blue. 
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Figure 11: Periodic acid staining of ZSF1 lean and ob/ob kidney samples. There are significant 
differences between lean and ob/ob rats’ kidneys. Accumulation of protein casts in tubules of ob/ob 
rats’ kidney (indicated with black arrows) are the sign of protein leakage. Mesangial expansion and 
sclerosis in the glomeruli and massive interstitial fibrosis are also seen. 
The striking differences between the renal phenotypes of the STZ-induced diabetic 
SD rats and the diabetic ZSF1 rat with metabolic syndrome lead us to address the 
hypothesis that, in the STZ-diabetic SD rats, additional factors are required to initiate 
renal pathologies.   
Thus, in the next experiment, we wanted to dissect the effect of hypertension from a 
combined effect of hypertension and hyperglycemia and, in addition, to study the 
contribution of AT1R signaling in the podocytes to the progression of the disease. 
Therefore, we created different rat models using the same genetic background and 
the same treatment conditions. 
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Table 5: Clinical parameters obtained from lean and ob/ob rats. Parameters are summarized as mean ± SD.  To confirm the data statistically, a student’s t-test 
was performed.  Differences were considered significant with *p < 0.05.  The lean group represents a non-diabetic control.  The age is indicated in weeks. 
Group 
Body Weight [g] 
Week 8 Week 12 Week 13 Week 16 Week 22 Week 27 Week 30 Week 33 Week 37 Week 40 
Lean 277 ± 30 356 ± 13 367 ± 12 407 ± 14 445 ± 23 487 ± 20 492 ± 18 505 ± 20 516 ± 22 510 ± 25 
OB/OB 296 ± 15 462 ± 22 475 ± 24 529 ± 29 566 ± 33 599 ± 42 614 ± 44 631 ± 48 647± 51 657 ± 57 
Group 
Urinary Glucose Level [mg/24hr] 
Week 8 Week 12 Week 16 Week 22 Week 27 Week 30 Week 33 Week 37 Week 40 
Lean 0.3 ± 0.3 2.9 ± 1.0 3.2 ± 0.3 2.7 ± 0.9 3.2 ± 0.9 2.7 ± 1.2 2.8 ± 1.4 2.1 ± 1.1 3.2 ± 0.7 
OB/OB 3.1 ± 0.4 3011 ± 689 4629 ± 1064 1385 ± 1209 8419 ± 1395 7623 ± 2266 7566 ± 1368 4034 ± 247 2885 ± 1687 
Group 
Blood Pressure [mmHg] 
Week 12 Week 13 Week 16 Week 20 Week 25 Week 31 Week 33 Week 35 Week 37 Week 41 
Lean 157.5 ± 8.4 162.3 ± 5.9 163.1 ± 6.1 157.2 ± 5.2 152.3 ± 5.4 148.2 ± 6.9 144.0 ± 3.4 147.0 ± 5.5 148.6 ± 6.1 145.3 ± 3.6 
OB/OB 141.5 ± 6.0 168.2 ± 5.0 177.0 ± 6.9 164.3 ± 11.2 165.6 ± 5.4 172.3 ± 6.8 172.3 ± 5.6 171.3 ± 5.2 175.4 ± 5.2 178.7 ± 7.2 
Group 
Urinary Creatinine [mg/24hr] 
Week 8 Week 12 Week 16 Week 22 Week 27 Week 30 Week 33 Week 37 Week 40 
Lean 5.92 ± 0.98 10.77 ± 0.79 11.25 ± 1.72 11.23 ± 1.75 14.76 ± 1.66 13.14 ± 1.45 14.73 ± 1.43 13.96 v 2.27 16.32 ± 2.02 
OB/OB 3.81 ± 0.02 6.31 ± 1.02 7.24 ± 1.06 7.11 ± 1.38 9.88 ± 1.82 10.24 ± 1.72 10.44 ± 1.41 8.02 ± 1.53 10.48 ± 1.51 
Group 
Urinary Protein [mg/24hr] 
Week 8 Week 12 Week 16 Week 22 Week 27 Week 30 Week 33 Week 37 Week 40 
Lean 13.98 ± 3.97 16.28 ± 3.01 15.27 ± 3.21 11.21 ± 3.53 13.51 ± 1.90 10.58 ± 2.25 15.67 ± 6.20 7.37 ± 3.41 14.24 ± 3.06 
OB/OB 8.25 ± 0.69 10.45 ± 5.19 44.19 ± 16.49 163.5 ± 48.67 257.2 ± 64.45 321.2 ± 97.82 356.2 ± 105 298.7 ± 116 373.9 ± 167 
Group 
Urinary Albumin [µg/24hr] 
Week 8 Week 12 Week 16 Week 22 Week 27 Week 30 Week 33 Week 37 Week 40 
Lean 221.8 ± 51.56 206.8 ± 35.26 255.5 ± 53.61 302.0 ± 94.47 695.4 ± 774 1394 ± 240 268.2 ± 144 349.0 ± 186 682.7 ± 420 
OB/OB 1106 ± 137 2529 ± 346 24619 ± 5763 119861 ± 33545 152174 ± 41867 
279378 ± 
104839 
258551 ± 
118225 
104345 ± 87634 304758 ± 104906 
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3.2 Hypertension and AT1R overexpression in podocytes synergistically 
stimulate rapid progression of glomerulosclerosis in STZ- diabetic rats 
3.2.1 Development of the rat models 
In order to compare the effects of hypertension with those of combined STZ-diabetes 
and hypertension under identical conditions, we used a transgenic Cyp1a1Ren2 rat 
which carries a transgenic renin gene under the control of the cytochrome P4501a1 
promoter and is located at the Y-chromosome. Transgene expression is induced by 
dietary supplementation with I3C which results in a dose-dependent hypertension 
within 24 hr. To mimic the natural progression of human DN, we induced 
hypertension after the induction of STZ-diabetes. In addition, we aimed to study the 
contribution of AT1R signaling in podocytes to renal damage. Therefore, we crossed 
a second transgenic rat line, the TGR Neph-hAT1, with the Cyp1a1Ren2 rats before 
starting the experiments. The Neph-hAT1 rat specifically overexpresses the AT1R in 
the podocytes, which leads to slowly progressing glomerulosclerosis in aged rats. 
The breeding procedure and experimental program are illustrated in Figure 12. The 
experiments started at the age of 6 weeks and were finished at the age of 14 weeks, 
a period before the TGRNeph-hAT1 rats start to develop disturbances in renal 
function and morphology. Since the Cyp1a1Ren2 transgene is located in the Y 
chromosome, all of the male progenies carry this transgene. Consequently, 
heterozygous female TGR Neph-hAT1 were crossed with male TGR Cyp1a1Ren2 to 
generate the genotypes Cyp1a1Ren2/Neph-hAT1TGR and Cyp1a1Ren2/wildtype. 
Then, the resulting male rats were subjected to the experiment while female rats 
were used for breeding. 6 weeks after birth, 60mg/kg of streptozotocin (STZ) was 
injected to the diabetic groups while others had no treatment. To induce hypertension 
two weeks after STZ injection, half of the non-treated group and half of the STZ-
injected group received an I3C supplemented diet until the end of the experiment in 
order to induce hypertension. Hereby, we have created the following experimental 
groups:  CTRL-TGR, CTRL-Wild, HBP-TGR, HBP-Wild, D-HBP-TGR and D-HBP-
Wild [Figure 12D]. Since the Cyp1a1Ren2 gene is silent when not induced by I3C, 
only rats harboring the transgenic AT1R were called “TGR” and rats without the 
transgenic AT1R are called “Wild”.  
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Figure 12: Mating scheme to create double transgenic rats and experimental groups. A- The male rat 
which carries the inducible renin gene (Cyp1a1Ren2) and the female rat which carries the Neph-hAT1 
receptor overexpressing gene (Neph-hAT1 TGR/Wild).  B- The female offspring which do not carry the 
CypA1Ren2a transgene but are either Neph-hAT1 (TGR) or Neph-hAT1 (Wild) for the AT1 receptor 
transgene. C- The male offspring which all carry the Cyp1a1Ren2 transgene but are either Neph-hAT1 
(TGR) or Neph-hAT1 (Wild) for the AT1 receptor transgene. D- Three experimental groups that have 
both Neph-hAT1 (TGR) and Neph-hAT1 (Wild) were designed each with TGR and Wild subgroup. 
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3.2.2 AT1R overexpression in podocytes does not affect hyperglycemia 
and blood pressure levels 
During the experiment, we regularly monitored blood glucose concentration and 
alterations in body weight and blood pressure. We also monitored water and food 
consumption and urine production using metabolic cages. Of note, there was no 
difference with regard to all of these parameters between CTRL-TGR and CTRL-Wild 
rats, indicating that AT1R overexpression alone did not affect any of the physiological 
parameters during the time of the experiment. In addition, the transgenic inducible 
renin gene did not affect any of these parameters in the controls, indicating that it is 
not expressed in the absence of I3C [Figure 13, 14, 15 and 16]. These facts were an 
important precondition for the experimental aim to dissect the effects of hypertension 
from those of combined hyperglycemia and hypertension and to specify the role of 
AT1R in podocytes in these pathologies. 
 
STZ induced hyperglycemia in all treated rats while non-treated rats did not show any 
changes in blood glucose concentration throughout the experimental period. The 
blood glucose levels did not differ between the treated groups – D-HBP-Wild and D-
HBP-TGR [Figure 13]. Diabetic rats showed the typical features of type-1 diabetes, 
including diuresis, increased water consumption and body weight loss, which also did 
not differ between D-HBP-TGR and D-HBP-Wild [Figure14, 15 and 20].  Blood 
pressure increased within 24 hours after induction and stayed stable until the end of 
the experiment. There was no difference in blood pressure between HBP and D-HBP 
and between TGR and Wild groups [Figure 16]. 
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Figure 13: Blood glucose concentration. A- Blood glucose of the rats two weeks after the STZ 
injection. Blood glucose levels rapidly increased in the D-HBP group due to the STZ injection while it 
remained steadily low for CTRL and HBP rats regardless of the genotype. B- Progressive 
measurement of blood glucose concentration of the rats from the beginning of the experiment to the 
end of the experiment. No significant differences have been observed between TGR and Wild in the 
same experimental group.  
** p< 0.01 vs. CTRL, ##p<0.01 vs. HBP.    
 
 
 
 
 
Figure 14: Urine production per 24 hr. A- Urine production is normal in all groups before starting the 
experiment. B- Both genotypes in the D-HBP group show polyuria at a similar level at the end of the 
experiment. No significant differences have been observed between TGR and Wild in the same 
experimental group. ** p< 0.01 vs. CTRL, ## p<0.01 vs. HBP.   
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Figure 15: Water consumption during the experiment. A- Water consumption of the rats at the 
beginning of the experiment, before STZ injection. B- Water consumption of the rats two weeks after 
STZ injection and before I3C intake. D-HBP rats consumed significantly more water than CTRL and 
HBP rats. C- Water consumption of the rats at the end of the experiment, six weeks after STZ 
injection. CTRL and HBP rats do not show any changes in water consumption while it was significantly 
greater in the D-HBP group. No significant differences were observed between TGR and Wild rats in 
the same experimental group. ** p< 0.01 vs. CTRL, ##p<0.01 vs. HBP.   
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Figure 16: Blood pressure of rats. A- Blood pressure of all rats at the beginning of the experiment. No 
differences were observed. B- Blood pressure of the rats after I3C intake. Blood pressure of the rats 
which received I3C dramatically increased within 24-48 hours. C- Blood pressure of the rats at the end 
of the experiment, 6 weeks after I3C intake. All the rats which received I3C have shown a comparable 
steady high blood pressure until the end of the experiment. D- Blood pressure changes over the time. 
No significant differences were observed between TGR and Wild rats in the same experimental group 
and between HBP and D-HBP groups. ** p< 0.01 vs.CTRL. 
 
3.3 Hyperglycemia and hypertension together aggravates renal damage, 
which is further enhanced by AT1R in podocytes 
3.3.1 Renal function 
 
In order to evaluate renal function throughout the experimental period we studied 
clinical parameters in blood plasma and 24hr urine and performed transcutaneous 
measurements of GFR using fluorescein isothiocyanate (FITC)-Sinistrin. Figure 17 
demonstrates a strong increase in the half-life of FITC-sinistrin clearance in the D-
HBP groups, indicating a significant drop in GFR. In contrast, the GFR was only 
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slightly decreased in the HBP-TGR group when compared with controls. Of note, the 
GFR dropped significantly more rapidly in the D-HBP-TGR compared to the D-HBP-
Wild rats. Thus, activated AT1R signaling in podocytes seems to be an important 
determinant in the progression of glomerular damage, specifically in DN.  
The decline in the GFR corresponds well with the increase in the albumin and protein 
excretion/24 hours [Figure 18]. The urinary protein and albumin excretions were 
moderately increased in the HBP-TGR but not in the HBP-WT group. In contrast, 
corresponding to the decline in GFR, the albuminuria increased dramatically in the D-
HBP groups. Again, the severity of albuminuria was significantly more pronounced in 
the D-HBP-TGR than in the D-HBP-Wild group, supporting the detrimental role of 
AT1R signaling in podocytes for the progression of DN.  
 
Figure 17: Transcutaneous GFR measurement by FITC-Sinistrin half-life. A- Two weeks after the 
induction of diabetes. No significant differences were observed among the experimental groups. B- 4 
weeks after IC3 intake. There is no difference in GFR between CTRL-TGR and CTRL-Wild. In the D-
HBP group, GFR dropped significantly in both TGR and Wild rats; however, the drop is significantly 
more pronounced in the TGR compared to Wild rats. FITC-Sinistrin half-life was slightly increased in 
HBP-TGRs compared to the CTRL rats. * p< 0.05 , ** p < 0.01 vs. CTRL, #p<0.05 vs HBP, + p<0.05 
vs Wild 
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Figure 18: Urinary protein and albumin excretion at experimental week 7.  In D-HBP rats, there is a 
considerable increase in both, urinary protein and albumin excretion vs. CTRL and HBP rats. This 
increase is significantly more pronounced in D-HBP-TGR than in D-HBP-Wild rats. Both parameters 
were also slightly increased in HBP-TGR rats while HPB-Wild and CTRL rats did not differ.  
** p< 0.01 vs. CTRL, #p<0.05 vs HBP of the same genotype, + p<0.05 vs Wild of the same group. 
 
 
The deterioration of renal function resulted in increased plasma urea levels in the D-
HBP groups [Figure 19] when compared with the CTRL and HBP groups. There was 
no difference between plasma urea levels of HBP and CTRL groups. In contrast, the 
plasma creatinine levels decreased in the D-HBP groups, which was probably a 
result of muscle weight loss due to diabetes. In addition, plasma cholesterol and 
triglyceride levels were significantly increased in the D-HBP groups. This increase 
was highest in the D-HBP-TGR group. Interestingly, a moderate increase in plasma 
cholesterol was also observed in the HBP-TGR group in contrast to the HBP-Wild 
group, when compared with CTRL.  
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Figure 19: Urea, Creatinine, Cholesterol and Triglyceride concentration in blood plasma at 
experimental week 7. A- Plasma urea concentration. D-HBP group have shown the highest urea 
concentration in plasma while both CTRL and HBP group shown no difference among. There was no 
significant difference between TGR and wild in any corresponding group. B- Plasma creatinine 
concentration. Here, plasma creatinine concentration was the lowest in D-HBP group while CTRL and 
HBP group have shown the same level of creatinine concentration. C- Plasma cholesterol 
concentration. Unlike CTRL group, D-HBP and HBP rats have revealed increased cholesterol level in 
plasma. Interestingly, TGR rats have significantly shown the highest cholesterol concentration in their 
corresponding groups. D- Triglyceride concentration in blood plasma. Here, triglyceride concentration 
revealed increase in D-HBP-TGR, D-HBP-Wild and HBP-TGR groups.  
** p< 0.01 vs. CTRL, #p<0.05 vs HBP of the same genotype, + p<0.05 vs Wild of the same group. 
 
3.3.2  Renal structure and morphology 
At the end of the experiments, kidneys were harvested for histological evaluation. 
Figure 20 shows an increase in the kidney/body weight ratio in the D-HBP groups, 
which might indicate hypertrophic growth. However, it is more probable that the 
decreased body weights in the D-HBP groups account for the increased ratio. The 
absolute kidney weights did not differ between the groups.  
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In order to verify whether hypertension or diabetes was associated with glomerular 
hypertrophy, we stained kidney sections with hematoxylin and eosin and determined 
the glomerular area. Figure 20 shows that, at the end of the experiment, the 
glomerular area did not differ between non-treated CRTL-TGR and CRTL-Wild. Thus, 
at that age, transgenic overexpression of the AT1R did not affect glomerular growth 
in untreated rats. However, in the HBP group, we observed a significant increase in 
glomerular size in HBP-TGRs comparable to that in D-HBP rats but not in the HBP-
Wild. These data indicate that the level and/or duration of hypertension in this 
experiment were insufficient to cause hypertrophic growth per se in HBP-Wild. 
However, the overexpression of the AT1R in podocytes together with hypertension in 
the HBP-TGR group stimulates glomerular hypertrophy. In contrast, both D-HBP 
groups, independent from their genotype, show significant glomerular hypertrophy. 
Consequently, the synergistic actions of diabetes and hypertension are required to 
induce hypertrophic growth of the glomerular tuft. There was no difference in the 
glomerular area between the hypertrophic glomeruli of the HBP-TGR, D-HBP-TGR 
and D-HBP-WT groups. Thus, glomerular hypertrophy alone cannot explain the 
significant differences in the renal function we observed between these groups. 
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Figure 20: Bodyweight (BW), kidney weight (KW), the ratio of BW/KW and glomerular area. A- 
Bodyweight of experimental rats. No difference has seen between TGR and Wild rats in corresponding 
groups. However, rats in D-HBP group shown the lowest body weight. B- Kidney weight of the rats. C- 
BW/KW ratio. Here, D-HBP group have shown the highest value in ratio due to diabetes dependent 
the weight loss. D- Glomerular area. D-HBP and HBP rats have shown enlarged glomerular area. TGR 
rats in both groups have shown a slightly bigger glomerular area than the wild ones.  
** p< 0.01 vs. CTRL, #p<0.05 vs HBP of the same genotype, + p<0.05 vs Wild of the same group. 
 
To study the glomerular lesions in more detail, Richardson’s staining of semi-thin 
kidney sections and electron microscopy were performed by Prof. Kriz, 
Neuroanatomy, Medical Faculty Mannheim and by Prof. Gröne DKFZ, Heidelberg. 
Light microscopy [Figure 21]. Electron microscopy [Figure-22] images of glomerular 
profiles from a D-HBP-TGR show the acute injuries we found in this group and 
partially in the HBP rats. Figure 21 A, B, C and E show prominent mesangial 
expansion, which might represent a first reaction to the increased blood pressure. In 
Figure 21B, huge hypertrophied podocytes are visible, indicating a compensatory 
reaction for the possible loss of podocytes. Detached, viable podocytes protruding 
into the urinary orifice are shown in Figure 21C.  Figure 21D shows irregular 
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unfolded large capillaries, indicating that the supporting function of the mesangium is 
impaired. This causes an extension of the glomerular tuft close to the parietal 
epithelial cells, promoting the attachment of podocytes and might initiate focal tuft 
adhesion to the Bowman’s capsule. Figure 21E demonstrates a significant tuft 
adhesion comprising almost two-thirds of the tuft and massive mesangial expansion. 
Shear stress drags the glomerular tuft towards the tubular opening. Bottle shaped 
podocytes, likely a result of high shear stress due to the rapid flow of the filtrate which 
makes the podocytes prone to detaching. In Figure 21F, advanced massive 
mesangial expansion and numerous detached podocytes in the Bowman’s space can 
be observed. On both sides of the glomerulus, massive intra-tubular protein casts are 
visible. Figure 21G shows advanced renal damage, comprising a collapsed 
glomerulus with tubulopathy. Although some of the pathologies were also observed 
in the HBP group, the frequency and severity of glomerular lesions were significantly 
increased in the D-HBP group, with the D-HBP-TGRs much more severe affected 
than the D-HBP-Wild rats. Figure 21H demonstrates that the majority of glomeruli 
were seriously damaged in the D-HBP-TGRs. 
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Figure 21: Light micrographs of glomerular profiles in a D-HBP-TGR rat showing the crucial injuries. 
A- Mesangial expansion, B- Mesangial expansion and hypertrophied podocytes C- Podocytes are 
protruding into the urinary orifice. D- Irregular large capillaries indicating that the supporting function of 
the mesangium is impaired. The glomerular tuft is expanded close to the parietal epithelial cells, 
promoting attachment of podocytes. E- Large tuft adhesion comprising almost two-thirds of the tuft. 
Mesangial expansion. Shear stress drags the glomerular tuft toward the tubular opening. Bottle 
shaped podocytes (arrow), likely a result of high shear stress due to the rapid flow of the filtrate – 
being prone to detachment. F- Massive mesangial expansion and detached podocytes in the 
Bowman’s space. G- Collapsed glomerulus with tubulopathy H- Overview of a kidney region showing 
severe glomerular damage.  
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Electron micrographs are shown in Figure 22. Remarkable, we observed thickening 
of the GBM and deposition of worn-out GBM material in the mesangium of the D-
HBP-TGRs similar to the findings of Kriz14 in patients with DN [Figure 22A]. Figure 
22B shows huge pseudocysts and in Figure 22C and D widened podocyte FPs can 
be observed. A complete FPE can be seen in two neighboring capillaries in Figure 
22E. Figure 22F shows tuft adhesion to the Bowman’s capsule. 
In order to quantify the damage profile, we performed AZAN staining on renal 
sections. In Figure 23, representative pictures of glomeruli in the different 
experimental groups are shown. The most severe damage was found in the D-HBP-
TGR group. PAS staining of D-HBP-TGR shows severe FSGS and massive 
intratubular protein casts.  
For quantification, we designated five categories of glomerular damage from healthy 
(G0) to the most severely damaged with adhesions to the Bowman’s capsule (G4). 
We evaluated an average of 180 glomeruli per rat. As shown in Figure 24, the most 
severe damage was found in the D-HBP-TGR group with 70.3 % of glomeruli were 
injured, including 26 % in the most severely damaged category G3 and G4. In 
contrast, in the D-HBP-Wild group, only 25.9 % of the glomeruli were injured and only 
3.3 % of glomeruli were in the G3 and G4 group. The prominent damage in this group 
was restricted to mesangial expansion. In the HBP group, the glomerular injuries 
were significantly less than in the D-HBP group and the differences between TGR 
and Wild much less distinct (damaged glomeruli: 16,4% in HBP-Wild, 30% in HBP-
TGR). These results correspond well with the functional data described above.  
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Figure 22: Representative images of transmission electron microscopy (TEM) in a D-HBP-TGR rat. 
A- Thickening of GBM and deposition of worn-out GBM in the mesangium B- Pseudocysts C+D- 
Widened podocyte FPs are attached to the GBM E- FPE at two neighboring capillaries F- Adhesion of 
the glomerular tuft to the Bowman’s capsule. 
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Figure 23: Representative light microscopic images of renal damage in the different genetic and 
treatment groups. Top (6 images): AZAN staining of the kidney sections reveals the most severe 
damage in the D-HBP-TGR group. Bottom (2 images): PAS staining of D-HBP-TGR kidney sections 
reveal massive FSGS and intratubular protein casts.  
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Figure 24: Representative AZAN stained images for 4 categories used to determine the damage 
index (AZAN staining. G0- healthy glomerulus stained fairly mild blue. G1- glomerulus stained mild 
blue representing the first signs of mesangial expansion. G2- moderately blue-stained glomeruli and 
mesangial expansion. G3- Severely blue-stained glomerulus and thickening in Bowman’s capsule 
together with mesangial expansion. G4- mostly blue-stained glomerulus showing adhesion to the 
thickened Bowman’s capsule. Damage index chart shows the distribution of the G0, G1, G2, G3 and 
G4 in percentages. D-HBP-TGR rats have had the most severely damaged glomeruli out of all groups. 
 
3.4 Conclusion I  
Our data demonstrate that the synergistic action of diabetes and HBP is required to 
induce rapid renal damage in diabetic rats since neither HBP alone nor STZ-diabetes 
alone was able to induce a comparable deterioration in renal function and 
morphology. AT1R overexpression in podocytes strongly accelerates the disease 
progression, specifically in D-HBP conditions.   
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3.5 Expansion microscopy enables nanoscale evaluation of the renal 
filtration barrier 
The evaluation of characteristic histological lesions in the GFB, such as podocyte 
FPE and GBM thickening so far required electron microscopy, since the fine structure 
of the GBM is in the nanoscale range below 100 nm. Thus, it cannot be evaluated by 
light microscopy as the physical diffraction limit of optical microscopes prevents high-
resolution imaging below 250nm. Recently developed Super-Resolution Microscopy 
solved this problem; however, it requires expensive microscope techniques and a 
highly skilled operator. In the present study, we aimed to use a recently developed 
technique ExM, to visualize and quantify alterations in the nano-scale structure of the 
GBM.  
ExM has solved three very important problems in the field. 
• It enabled the visualizing of nano-scale structures by the use of the 
fluorescent or confocal microscope. 
• It enabled the labeling of the structure of interest using classical 
antibodies and immunohistochemistry. 
• It enabled the volumetric evaluation of thick tissue slices and the 
creation of 3D models of the structure of interest at the nanoscale 
range. 
 
3.5.1 Workflow of ExM on kidney samples 
Our protocol is in principle based on a procedure described in 2018111. The workflow 
of our experiments is shown in Figure 25 and described in more detail at the material 
and method section. After clearing and denaturation, the kidney sample has 
expanded roughly 1.8 times and becomes fragile. For immunohistochemistry, these 
slices were cut from the cortex to the medulla into different sections each containing 
cortical and medullary parts, which were used to stain with different antibodies or 
used to store at 4°C. Thereafter, samples were first imaged at the confocal 
microscope and then further expanded by placing the sample into ddH2O for 1 day. 
Compared to the original size, the kidney is finally expanded by roughly 4.5 times. 
The second and final imaging is then performed. The immunostaining before the final 
expansion has the advantage that lesser antibodies are needed, and the tissue gel is 
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less fragile. The expanded tissue consist of more than 90% water. Thus, the 
autofluorescence is strongly reduced. One sample can be repeatedly stained. 
Therefore, the tissue is shrunken again by placing it into 1x PBS, the antibody is 
removed due to repeating the denaturation step and the immunohistochemical 
staining procedure is repeated. 
 
Figure 25. Workflow for expansion microscopy. A- Entire kidney sample after perfusion. Then, this 
kidney was cut into several pieces, and the mid-part was placed into AHS after overnight postfixation 
in 4% PFA at 4 °C. B- Kidney sample after polymerization of AHS solution at 37 °C. C- Polymerized 
sample was cut via vibratome at the desired thickness (1mm to 50 μm). D- Kidney slices after clearing 
and denaturation in denaturation solution at 70 and 95°C each for 12 hr (500 µm thickness). Then, the 
sample becomes transparent (and expanded approximately 2 fold). E- Sample placed into ddH2O and 
expanded. Immunostaining was performed after the denaturation. 
 
 
3.5.2 Immunohistochemistry 
To label the SD between the secondary FPs, we used nephrin, a major constituent of 
the SD. The intracellular tail of nephrin directly binds to podocin, which is located at 
the insertion site of the SD in the podocyte secondary FPs. We used podocin staining 
to outline the secondary FP. The width of the FP was determined by the distance 
between two podocin stains. A key feature of glomerular diseases is podocyte FPE, 
which includes the retraction of the secondary FP and is associated with their 
widening in Figure 26. Furthermore, we stained collagen IV, the main constituent of 
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the GBM which also label the Bowman’s capsule. Co-staining of nephrin and 
collagen IV allows the study of glomerular tuft volume, the size of the Bowman’s 
capsule and GBM thickening [Figure 27]. 
 
 
Figure 26: Arrangement of the podocyte foot process in Scanning Electron Microscopy (SEM). A- FPs 
are tightly attached and well organized. B- FPs are retracted and effaced. Red lines (drew by us) 
represent SD, namely nephrin. *Originally published in Endlich et al. 2018 
 
 
 
Figure 27: Immunohistochemical staining of glomerular structures. A- Podocin staining labels the 
membrane of the podocyte secondary foot processes outside of the capillary tuft. B- Nephrin staining 
labels the slit diaphragm and thus, generates a similar picture as the podocin staining. C- Collagen IV 
staining labels the basement membrane and parietal epithelium. D- Co-staining of nephrin and 
collagen IV.      
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3.5.3 Visualization of slit diaphragm and podocyte foot processes by ExM 
and confocal microscopy 
The physical expansion of the tissue dramatically increased the resolution. Figure 28 
shows immunohistochemistry for podocin on a non-expanded 4μm kidney section 
and on an expanded 500µm section. The 4μm kidney section was stained with 
podocin and synaptopodin antibodies. The 500μm sections were stained with a 
podocin antibody and expanded using the ExM technique. The 4 μm samples were 
imaged by the use of a 63x (oil immersion) objective. The 500 μm samples were 
imaged using a 20x (water immersion) objective. Despite less magnification used to 
image the expanded tissue, the resolution was much higher than in the non-
expanded tissue, as shown in Figure 28. ExM enabled the visualizing of the podocin-
labeled podocyte FPs. Figure 29 shows a comparison of podocyte FPs in rat kidneys 
we imaged by ExM and confocal microscopy with those generated by SIM, which 
was prepared by Prof. N. Endlich, University Greifswald, NIKOPA, Greifswald using 
the same tissue. It is clear that ExM provided a comparable resolution as SIM. 
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Figure 28: Comparison of the resolution of the classical IHC to ExM. A and B- 5μm thick sample 
stained with Podocin (red) and Synaptopodin (blue) by classical IHC (60x oil immersion objective).C- 
Merge image of A and B. D- Magnification of the podocyte foot process on 4μm thick sample stained 
with classical IHC. E- 4μm thick sample stained with podocin (red) by using classical IHC (63x oil 
immersion objective). F- Magnification of the area labeled on the image E. G- Podocin stained 
glomerular structure and podocyte foot process (stained red) in 500μm expanded kidney sample (20x 
water immersion). H- Magnification of the yellow labeled area on the image G. 
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Figure 29: Comparison of Expansion Microscopy technique (ExM) and Structured Illumination 
Microscopy (SIM). A- 500μm thick kidney sample stained with Podocin (red) and expanded (20x water 
immersion objective). B- Super-resolution microscopy images of the mouse kidney (**published by 
Endlich et al. 2018). 
 
3.5.4 Expansion factor and distortion 
An important issue we addressed was the determination of the expansion factor. The 
expansion factor was calculated for each individual rat and was used to normalize 
morphometric measurements. Moreover, we wished to evaluate whether ExM causes 
any distortion of the samples’ structure, which might affect the results of 
morphometric measurements. From each rat, a part of the kidney was frozen for H&E 
staining and used as a “non-expanded control samples”, and another part was used 
for ExM and stained for podocin. In both samples, the glomerular size was 
calculated, as shown in Figure-30. We measured the longitudinal and transverse 
diameters. Based on this, for each kidney, we calculated the expansion factor, which 
was later used to normalize the following morphometric measurements in the ExM 
tissues. The graphic illustration in Figure-30 demonstrates that the average 
expansion factors were equal for longitudinal and transverse diameters. They 
correlated with r= 0.97.  Alike, the expansion factor did not differ between the 
different treatment groups and genotypes. Moreover, as shown in Figure-31, the 
increase in glomerular size in HBP or D-HBP vs. CTRL was comparable, 
independent of whether it was evaluated using H&E staining on non-expanded 
tissues or ExM. Thus, these data indicate that morphometric measurements in the 
expanded kidneys are trustable for the evaluation of changes in tissue structure due 
to disease. Additionally we calculated the ratios between both glomerular diameters 
for each glomerulus to evaluate a possible distortion of the tissue during expansion. 
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As shown in Figure-31 the ratios were constant regardless of disease or whether 
using non-expanded or ExM tissue. 
Figure 30: Calculation of the expansion factor and evaluation of the expansion. A- Entire scan of the 
kidney section stained by H&E. B- magnification of the yellow labeled area. C- Representation of the 
measurements on two glomeruli. D- Expanded kidney sample and measurement of two glomeruli. E- 
chart representing the average expansion factor among the groups.  
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Figure 31: Expansion factor and distortion. Graphs showing the max. transverse and max. longitudinal 
glomerular diameters. Both are comparably increased in the HBP and D-HBP group vs. controls 
independently, whether measured in non-expanded or expanded tissue. In contrast, the ratios 
between the max. transverse and max. longitudinal glomerular diameters were similar in all groups, 
indicating that the tissue uniformly expanded.    
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3.5.5 Glomerular damage correlates with FPE - evaluated by ExM vs. SIM 
and electron microscopy 
We used the described method to evaluate the podocyte FPs in order to quantify the 
FP widths. Widening of FPs is a feature of FP retraction and associates with DN. As 
shown in Figure-32, ExM and podocin staining permitted us to image a larger renal 
area and to evaluate a number of glomeruli in 3D at low magnification (10x 0bjective) 
[Figure-32A]. Individual glomeruli were selected and evaluated in more detail using 
the 20x objective [Figure-32B]. Then selected glomerular regions were investigated 
in even more detail using the 63x objective to evaluate the FPs [Figure-32C and D].  
 
 
Figure 32: Deep imaging of the podocyte foot process in expanded kidney sample. A- 3D images of 
several kidney’s glomeruli, 10x objective. B- 3D images of a single glomerulus, 20x objective. C- 
Magnification of the labeled area on the B, 63x objective. D- Further magnification of the labeled area 
on the image C showing podocyte foot processes and slit diaphragm, 63x objective. 
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Interestingly, using this method, we often found structures never previously 
described, as shown in Figure-33 and which we cannot explain yet. These loops of 
interdigitating FPs, not anymore connected with the GBM, might represent a reservoir 
that is used to compensate pressure-related expansions of the capillary. These 
hypothesis needs to be further investigated. 
 
 
 
Figure 33: Figures showing intact interdigitating FPs which are not adhered to the GBM.   
 
Figures-34 - 38 show representative images from the kidneys of CTRL-TGR [Figure-
34], HBP-TGR [Figure-35] and D-HBP-TGR rats [Figure-36 - 38]. In CRTL rat 
kidneys, all the surfaces of capillaries are densely covered by long, narrow FPs 
interdigitating with each other [Figure-34].   
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Figure 34: Podocyte foot process of the expanded kidney sample in the CTRL group. A- 3D image of 
a single glomerulus. B- Magnification of the labeled area in A.  
In both, HBP-Wild and -TGR rat kidneys, the podocyte FPs network appear regular, 
the SD is intact and densely covers all capillaries, although the rats already 
developed to a certain degree albuminuria. However, it is obvious that the FPs widths 
are increased and the FPs are shorter [Figure-35]. In contrast, in D-HBP rats, 
specifically in D-HBP-TGR, we found severe injuries in the FP structure as shown in 
Figure-36-38. Within one glomerulus, there are areas of a still intact FP network with 
shortened and widened FPs, in other areas, the FPs are retracted, irregularly 
organized or podocin staining is completely lost indicating a complete FPE or not 
covered GBM with scarring. 
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Figure 35: Podocyte foot process arrangement of expanded kidney samples in the HBP group. A-3D 
images of the kidney’s glomerulus. B- Magnification of the labeled area in picture A. C- The 3D image 
of a kidney’s glomerulus. D- Magnification of the labeled area on image C. 
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Figure 36: 3D representation of the FPs arrangement in D-HBP-TGR. A- 3D distant image of a 
glomerulus. B- Magnification of the selected area with FPE. C- Magnification of the selected area to 
show ExM enables to visualize the arrangement of the fine structures in 3D, showing widened and 
shortened FPs. 
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Figure 37: Podocyte foot process arrangement of expanded kidney samples in the D-HBP-TGR 
group. A- 3D overview image of the kidney’s glomerulus. B- Magnification of the labeled area in picture 
A showing FPE. C- The 3D image of a kidney’s glomerulus. Arrows indicate areas where the FPs 
structure is completely lost. D- Magnification of the labeled area on image C showing severe FPE.  
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Figure 38: Podocyte FP arrangement of expanded kidney samples in the D-HBP-TGR group. A- 3D 
images of the kidney’s glomerulus. B- and C- Magnification of the labeled area in picture A. showing 
severe FPE and loss of FP structure (arrows). 
 
 
The FP widths were calculated by measuring the distances between the podocin 
stainings [Figure 39] of 150 FPs in 5 different regions of each of 2-3 glomeruli per  
rat.  
 
Figure 39: Representative image showing the measurement of podocyte FP widths and SD widths. 
Here, the space between podocyte foot processes are clearly shown by ExM. 
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Using paraffin sections from the same kidneys, the group of Prof. N. Endlich in 
Greifswald (University Greifswald/NIKOPA) determined the podocyte filtration slit 
density (FSD) by SIM and a software-based approach PEMP. They previously 
demonstrated a high correlation between the FSD and with FP width106. Figure-40 
shows representative ExM images of CRTL, HBP and D-HBP rat kidneys with 
podocin stained podocyte FPs in comparison to nephrin stained podocyte FPs 
imaged SIM. The resolution and quality of images using ExM are clearly comparable 
with SIM.  
 
 
Figure 40: Comparison of the FPs arrangement in ExM and SIM. In ExM technique, we observed that 
CTRL group has relatively long FPs, and FPs are well organized; however, this organization is 
moderately altered in HBP rats. FPs are effaced and distorted in D-HBP rats. The same pattern is also 
observed by SIM technique, which was performed by N. Endlich, University Greifswald/NIKOPA 
 
Figure 41 shows the calculated FP widths of TGR and Wild in the three experimental 
groups CRTL, HBP and D-HBP. Both TGR and Wild show a significant increase of 
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the FPs widths in HBP rats and a further significant increase in the D-HBP rats. 
Within the D-HBP group the TGR-FP-width is significantly increased vs. the Wild-FP-
widths. The FSD data obtained by SIM and FP width obtained by ExM highly 
correlated with the correlation coefficient of r=-0.975. An increase in FP width 
corresponds to a decrease in FSD. Further, the FP width corresponds well with the 
damage index determined in paraffin sections, the albuminuria and the degree of 
GFR deterioration.  
 
 
Figure 41: Comparison of the SIM determined FSD and ExM determined FP widths. A- Foot process 
widthd determined by ExM. Here, the D-HBP group has shown the greatest width, presumably due to 
the FPs retraction. B- Filtration slit density of the experimental rats determined by SIM and PEMP. 
Glomerular damage index (in percentage) 
 
3.6 Conclusion II 
Expansion microscopy is a useful tool for nanoscale evaluation of the GFB in rats 
with glomerular diseases and provides similar results concerning the FP architecture 
as SIM technology. The FP widths strongly correlate with increases in albuminuria 
and the damage index and decreases in GFR. Although HBP induced a certain 
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albuminuria, the FP architecture is preserved, however, FP widths are increased, and 
the FP lengths are shortened.  
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4 DISCUSSION 
DN is a leading cause of end-stage renal disease and affects 30% of diabetic 
patients116, 120. Thus, 70% of diabetic patients are protected from DN, indicating that, 
besides hyperglycemia, DN requires additional factors to develop.  Despite major 
advances in our understanding of the disease, the molecular pathogenesis of DN 
remains far from clear. A major barrier to further progress is the lack of a suitable 
diabetic animal model that mimics human DN. Existing diabetic models mostly exhibit 
only the earliest features of human DN121. Rodent models that develop 
pathohistological alterations in the kidney, like the ob/ob mouse or the ZSF1 rat, are 
also hypertensive and/or obese. Thus, it has been difficult to separate the 
hemodynamic from non-hemodynamic effects in vivo. DN is characterized by severe 
albuminuria, renal hyperfiltration, GBM thickening and glomerulosclerosis115 and the 
currently first-line therapy is blocking Ang II.  
The present study had two major aims. First, to develop suitable rat models to 
compare the effects of diabetes, hypertension and combined diabetes/hypertension 
on the kidney and to specify the role of Ang II signaling in podocytes in this context. 
Second, to establish and verify an ExM method, which enables the visualization of 
the podocyte FPs in these disease models and to quantify the degree of FPE.  FPE 
of podocytes is a typical feature of DN and is associated with the leakage of the GFB. 
It requires electron microscopy to diagnose since the fine structure of GFB is in the 
nanoscale range.  
The key findings of this study are; 
1. For the development of DN in rats, HBP and hyperglycemia has to synergize, 
since neither HBP alone nor STZ-diabetes alone was able to induce a comparable 
deterioration of renal function and pathohistological alterations in the kidney. AT1R 
overexpression in podocytes strongly aggravated the renal damage in D-HBP rats 
and to a less degree also in HBP rats.  
2. ExM is a useful tool for the nanoscale evaluation and quantification of the 
alterations in podocyte FPs architecture by light microscopy. The determined FPs 
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width strongly correlated with albuminuria, the damage index and the decreases in 
GFR.  
4.1 Hyperglycemia do not induce diabetic nephropathy in SD rats 
Previous experiments in our group characterized the effect of STZ diabetes on the 
kidneys of Sprague Dawley rats. We used this rat line because our transgenic 
NephAT1R rat was generated on this background. Although the rats developed 
clinical diabetes early, indicated by increased glucose levels in the plasma and urine, 
polyuria, and polydipsia, the urinary albumin excretion increased only slightly 
(7mg/14hr in diabetic rats vs. 0.5 mg/24hr in controls) 7 months after onset of 
diabetes and no pathohistological alterations in the kidney developed. Besides 
hyperfiltration, increased albumin excretion is one of the first clinical sign for DN and 
points to the weakness of the filtration barrier. Next, we studied the ZSF1 ob/ob rat 
which spontaneously develops diabetes, including a metabolic syndrome117. In 
contrast to the STZ-diabetic rats, seven months after the onset of hyperglycemia, 
hypertension and obesity the ZSF1 rats exhibited severe renal injury, including 
prominent glomerulosclerosis, tubular atrophy and tubulo-interstitial fibrosis and 
severe albuminuria. Thus, DN in rats requires further factors interacting with 
hyperglycemia.  
4.2 Hypertension and AT1R overexpression in podocytes accelerate rapid 
progression of renal failure in STZ-diabetic rats 
In order to dissect the synergistic actions of hyperglycemia with hypertension from 
those of hypertension alone, we used the TGRCyp1a1Ren2 rat97.  This rat carries a 
transgenic renin gene driven by the P4501a1 promoter, such that dietary I3C 
supplementation dose-dependently induces transgene expression resulting in 
controlled hypertension within 24 h. In order to specify the role of AT1R signaling in 
podocytes under these pathological conditions, we crossed the TGRCyp1a1Ren2 rat 
with heterozygous Neph-hAT1R rats (TGR)39 to generate CRTL, HBP and D-HBP 
groups with TGR and Wild as subgroups in each. We induced diabetes by STZ-
injections followed by I3C induced HBP two weeks later. This approach enabled us to 
Discussion 
87 
 
 
study the effects of HBP and synergistic D-HBP on the kidney in the presence (TGR) 
and absence (Wild) of AT1R overexpression under identical conditions and on the 
same genetic background.  
The TGRNeph-hAT1R rat model was previously developed in our lab39. The AT1R 
overexpression in podocytes causes FSGS and renal failure in old rats. That’s why it 
is important to know that throughout the experimental period the TGR-CTRL did not 
differ from the Wild-CTRL and exhibited normal values in all the parameters we 
tested including blood glucose, blood pressure, renal function, GFR, albumin 
excretion, clinical parameters in the plasma, kidney weight and glomerular tuft size. 
In addition, kidney morphology was normal in both groups. Moreover, HBP and D-
HBP groups of both genotypes had comparable blood pressure and blood glucose 
levels. Thus, the AT1R in TGRs did not influence these parameters and the observed 
differences between diseased TGR and Wild groups directly result from the 
interaction of AT1R overexpression in podocytes and the disease conditions. 
While STZ-diabetes by itself required 7 months of diabetes to induce only the earliest 
signs of DN - a mild micro-albuminuria of 8 mg/day without structural changes in the 
kidney, within 8 weeks hyperglycemia and hypertension synergistically caused renal 
damages including severe albuminuria (~200 mg/24hr), a significant drop in GFR, 
significant glomerular hypertrophy and glomerular lesions. In contrast, hypertension 
alone only had minor effects on the kidney. These data correlate well with the 
findings of the Mullins group who found a human DN like phenotype in rats 7 months 
after combined induction of diabetes and hypertension98.   
AT1R overexpression in podocytes remarkably aggravated the disease progression 
in the D-HBP and to a less extend also in the HBP group. Within 8 weeks of diabetes, 
only the D-HBP-TGRs showed the advanced stages of DN with widespread 
glomerular sclerosis and a remarkable drop in GFR. They developed all the typical 
features of DN, including GBM thickening, mesangial expansion and FSGS. 70% of 
the glomeruli were damaged and 26.1% of glomeruli were classified into the 2 most 
severe categories of the damage index. In comparison, in D-HBP WT, only 26% of 
the glomeruli were damaged, and only 3.3% of glomeruli were classified into the 2 
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most severe categories. This points to a crucial role of the AT1R signaling in 
podocytes in DN but also indicates that the beneficial effects of RAS blocker in DN 
not only results from improved hemodynamic actions but also from interference with 
the AT1R signaling in podocytes.  
The mechanisms of AT1R signaling were intensively studied in this model and in 
vitro. The Gq coupled AT1R increase Rac1 expression41, 43, which leads to increased 
production of ROS43 and to vesicular insertion of the transient receptor canonical-5 
TRPC5 ion channel into the podocyte plasma membrane, making them available for 
activation by the AT1R. Consequently, transient Ca2+ influx into podocytes increases 
and further activates rac1, feeding a circuit that promotes podocytes cytoskeletal 
remodeling42. Excessive ROS production is accompanied by an AT1R induced down-
regulation of the anti-oxidative protein Prdx2 to maintain an oxidative environment in 
podocytes122. The Prdx family of peroxidases protects cells against oxidative 
damage. This AT1R-rac1-ROS pathway causes, via ERM proteins the 
phosphorylation of F-actin, cytoskeletal reorganization with stress fiber attenuation 
and a switch to a migratory phenotype43 including -actinin-4 down-regulation. Cross-
linking of actin filaments bundles by -actinin-4 is necessary for normal podocyte 
adhesion123. Notably, -actinin-4 interacts with integrin and enhances podocyte-
matrix interactions, preventing podocyte detachment. Thus, mutations in -actinin-4 
cause albuminuria124. The actin cytoskeleton network in podocyte FPs is linked to the 
GBM and slit membrane via different adapter molecules. Consequently, sustained 
AT1R signaling in the podocytes of TGRNeph-hAT1R rats may cause major changes 
to the F-actin cytoskeleton in FPs, impairs podocyte stability and podocyte adhesion 
and make them prone to detaching more easily from the GBM.  
This scenario might be amplified due to the direct deleterious effects of high glucose 
levels on podocytes. Glucose activates intracellular Ang II production in podocytes, 
increases ROS formation37 and the expression of another Ca2+ channel, TRPC6, via 
AT1R signaling125. Furthermore, both high glucose and Ang II weaken the density of 
the GFB by decreasing the expression of proteins involved in the SD signaling 
complex, including nephrin, CD2AP and podocin, as well as synaptopodin, an actin-
associated protein that plays a role in podocyte shape and motility. 
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In both, HBP and D-HBP rats, the glomeruli and podocytes were challenged by 
comparable tension stress due to HBP and by an activated RAS due to transgenic 
renin production. Additionally, in the D-HBP model, the podocytes are also stressed 
by increased glucose levels, increased ROS126  and increased shear stress due to 
the hyperfiltration which occurs in early diabetes. Increased glucose, ROS and shear 
stress alone is not sufficient to induce any pathohistological alteration as we have 
demonstrated. Kriz’s group studied the effects of increased perfusion pressure on 
glomeruli127. He found that the GBM is the dominant structure generating wall tension 
to counteract expansion when pressure rises. He concluded that podocytes seem to 
be protected against the tensile stress by the limited distensibility of the GBM and 
their firm attachment to it. The mechanistically stability of the capillary network is 
largely maintained by the mesangial cells1. According to the findings of Kriz et al., 
increased perfusion pressure locally leads to a breakdown of the mesangial cell-GBM 
connection causing a displacement of the capillaries toward and into the urinary 
orifice, exposing the podocytes to the shear stress of the filtrate. In other situations, 
the capillaries and associated podocytes shifted radially, coming into contact with the 
parietal epithelium and starting to form tuft adhesions14. The second challenge is the 
activated RAS in the HBP and D-HBP group. Mesangial cells carry a high density of 
AT1Rs128. Overstimulation of these AT1Rs leads to proliferation and hypertrophy of 
mesangial cells and increased production of matrix components that might contribute 
to mesangial expansion42, 129. We observed in both the HBP and the D-HBP group, 
mesangial expansion and large, irregular capillaries as consequence of mesangial 
failure. Under these conditions, increased shear stress, due to hyperperfusion in the 
D-HBP group, seems to promote the detachment of podocytes from the GBM. Kriz et 
al. describes such podocytes as bottle shaped. A further challenge in the D-HBP rats 
is the thickened GBM as consequence of overproduction or reduced degradation of 
GBM material. Accumulation of worn-out GBM material substantially contributes to 
mesangial expansion in patients with DN14 and aggravates the above-described 
scenario. Electron microscopy revealed in the D-HBP-TGR rats bottle-shaped and 
detached podocytes and worn out GBM material in the mesangium, supporting the 
findings of Kriz in human DN patients130 and demonstrating the similarities between 
our rat model and human DN.  
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Thus, the aggravation of the disease progression in the D-HBP-TGR might result 
from the reduced resistance of the AT1R overexpressing podocytes to detaching 
from the GBM.  
In conclusion, the concerted action of an activated RAS with hemodynamic and 
hyperglycemic effects on the glomerulus is required to induce rapid glomerular 
injuries in diabetic rats. AT1R signaling in podocyte accelerates and amplifies 
glomerular injuries in this context, pointing to a crucial role of podocytes in the 
progression of DN.  
4.3 ExM enables to image and quantify nanoscale pathological changes in 
podocyte foot process morphology in diabetic nephropathy and 
hypertension 
Podocytes react with FPE to cellular stressors challenging their adhesion to the 
GBM. Thus, podocyte FPE is an important diagnostic marker for DN. FPE is a result 
of retraction, widening and shortening of the FPs and seems to be a protective 
response to prevent podocyte detachment. In the complete stage of FPE, podocytes 
broadly attach to the GBM by their cell bodies, having lost all of their processes. 
While the early stages of FPE might be reversible, podocytes detach if FPE reaches 
a point of no return. Adjacent FPs are bridged by the SD, with nephrin as a major 
constituent. The intracellular domain of nephrin binds to podocin in the SD insertion 
site. The fine structure of the GFB is in the nanoscale range and was previously only 
resolvable by using electron microscopy or the recently developed super-resolution 
microscopy. The SD functions as a molecular size filter and has a size of 30 nm. The 
normal width of individual FPs is roughly 250 nm127.  
In the present work, we used the recently developed method ExM111 which physically 
expands the kidney in a swellable gel to image the podocyte FPs. We labeled the 
secondary podocyte FPs and the SD by staining for podocin and nephrin, 
respectively. The advantage of ExM over EM is that it allows the study of thick tissue 
samples (500 nm) for a full volumetric 3D perspective of the whole glomeruli down to 
the podocyte FPs using confocal microscopy. A comparison between confocal 
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microscopy in expanded tissue and SIM from paraffin sections of the same kidney 
show similar results for both methods which highly correlated. A major concern was 
whether samples expanded uniformly. This was proven by calculating the ratio 
between the longitudinal and transverse glomerular diameter in non-expanded frozen 
sections and expanded kidney slices. This ratio was similar in all rats, independent of 
whether non-expanded or expanded tissue was used and whether the glomerular tuft 
was hypertrophied or not, as in the D-HBP and CTRL groups respectively, showing 
that the expansion was isotropic. Moreover, we verified the hypertrophic growth of 
the glomerular tuft size in HBP and D-HBP in both non-expanded and expanded 
tissue. The expansion factor for the maximal transverse and maximal longitudinal 
glomerular diameter was similar in all groups (r=0.97).  
Interestingly, HBP rats of both genotypes exhibited shortened and widened FPs 
that fully covered the glomerular tuft in a regular and well-organized manner, 
although these rats exhibited albuminuria, with 20-50-fold increased albumin 
excretion compared to controls. D-HBP-TGR rats, however, showed large glomerular 
areas with disorganized and flattened FPs indicating FPE, which was confirmed by 
EM in the group of Prof. Kriz, Neuroanatomy, Medical Faculty Mannheim. Moreover, 
many glomeruli contained regions in the glomeruli that have lost podocin staining 
indicating the presence of naked or sclerotic glomerular tuft areas. The FP widths in 
CTRL (250 nm) were in good agreement with previously published data111. The FP 
width determined by EM was somewhat lower (150 nm), which is comprehensible 
since the pretreatment of the tissue for EM shrinks the tissue. FP widths moderately 
increased in the HBP group but strongly increased in the D-HBP group by more than 
two-fold in the D-HBP-TGR group specifically. The average FP widths correlated well 
with the functional and morphological alterations in the kidney of the different groups. 
The D-HBP-TGR group exhibited the highest FP widths and most severe renal 
damage as evaluated by AZAN staining, semithin sections and by electron 
microscopy. In addition, the group of Prof. Nicole Endlich in Greifswald (University 
Greifswald, NIKOPA) evaluated the FPs in our rat kidneys using SIM microscopy. We 
determined the FP widths as the distance between two podocin stains. In contrast to 
us, NIKOPA used a program PEMP to calculate the nephrin stained density per area 
to evaluate the filtration slit density131. Of note, these results highly inverse correlated 
with our data (r=0.975), proving the capacity of ExM to reliably quantify the altered 
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morphology of FPs. Widening and shortening of the FPs in conditions of HBP seem 
to be an adaptive response of podocytes, which might be reversible and probably 
does not result in podocyte loss. An additional shear stressed caused by 
hyperfiltration due to diabetes might cause massive detachment of podocytes, 
promoted by increased AT1R signaling. In summary, this work demonstrates that 
renal damage in diabetic rats requires the synergistic action of HBP with 
hyperglycemia and that AT1R signaling in podocytes strongly aggravates the disease 
progression. Moreover, we demonstrate that ExM is a suitable method to quantify 
nanoscale alterations in the podocyte FP structure during different glomerular 
diseases.
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5 SUMMARY (ABSTRACT) 
DN is a leading cause of end-stage renal disease and affects 30% of diabetic 
patients116, 120. Thus, 70% of diabetic patients are protected from DN, indicating that, 
besides hyperglycemia, DN requires additional factors to develop.  Despite major 
advances in our understanding of the disease, the molecular pathogenesis of DN 
remains far from clear. A major barrier to further progress is the lack of a suitable 
diabetic animal model that mimics human DN. Existing diabetic models mostly exhibit 
only the earliest features of human DN121. A hallmark of DN is glomerulosclerosis. 
Leakage of the filtration barrier is one of the first clinical signs in DN and is 
associated with FPE and podocyte detachment. To diagnose these alterations 
required electron microscopy, since the fine structure of the GFB is in the nanoscale 
range. The currently first-line therapy is blocking Ang II.  
The following study target the hypothesis that excess AT1R signaling in podocytes 
aggravates DN, which might be induced by combined induction of STZ-diabetes and 
hypertension in rats. Thus, the present study had two major aims. First, to develop 
suitable rat models allowing to assess the role of hypertension for the development of 
DN and to specify the role of Ang II signaling in podocytes in this context. Second, to 
establish and to verify an ExM method, which enable the visualization and 
quantification of alterations in podocyte FP structure in the disease models.  To this 
end we crossed the TGRCyp1a1Ren2 developing hypertension after food 
supplementation with I3C with the TGRNeph-hAT1R rats overexpressing the AT1R 
specifically in podocytes. In part of rats, STZ-diabetes and high blood pressure were 
induced alone (HBP) or in combination (D-HBP). Renal function (GFR, albuminuria), 
blood pressure, clinical parameter in urine and blood were monitored. 
Pathohistological changes in glomeruli were determined by light microscopy, super-
resolution light microscopy and electron microscopy. Further we developed and 
validated a method to visualize nanoscale alterations in podocyte FPs and FPE by 
confocal microscopy using tissue expansion. The obtained results were verified by 
SIM technology on paraffin embedded tissue. 
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Our data demonstrate that the synergistic action of diabetes and HBP is required to 
induce rapid renal damage in diabetic rats since neither HBP alone nor STZ-diabetes 
alone was able to induce a comparable deterioration in renal function and 
morphology. AT1R overexpression in podocytes strongly accelerates the disease 
progression, specifically in D-HBP conditions.   
 Further, this thesis revealed that Expansion microscopy is a useful tool to 
diagnose FPE in DN and provides similar results concerning the FP architecture as 
SIM technology. The podocyte FP widths strongly correlate with increases in 
albuminuria and the damage index and decreases in GFR. Although HBP induced a 
certain albuminuria, the FP architecture is preserved, however, FP widths are 
increased, and the FP lengths are shortened. AT1R signaling in podocytes strongly 
accelerated FPE in DN probably by increasing their sensitivity to be detached in 
stress conditions.      
In summary, this work demonstrates that renal damage in diabetic rats 
requires the synergistic action of HBP with hyperglycemia and that AT1R signaling in 
podocytes strongly aggravates the disease progression. Moreover, we demonstrate 
that ExM is a suitable method to quantify nanoscale alterations in the podocyte FP 
structure during different glomerular diseases. 
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7 APPENDIX 
Appendix-A: Blood glucose concentration over the time. Wild=Wild Type, TGR=Transgenic, CTRL= 
Control rats, HBP= Rats fed by the pellet food with I3C, D-HBP=Diabetic rats fed by the pellet food 
with I3C, N =number of rats in the group. 
 
Sex 
Age 
(weeks) 
Group Genotype N 
Blood 
Glucose 
Concentration Sex 
Agen 
(weeks) 
Group Genotype N 
Blood 
Glucose 
Concentration 
[mg/dL] [mg/dL] 
Male 
Week-0 
CTRL 
Wild 10 
121.001 ± 
5.457 
Male 
Week-4 
CTRL 
Wild 10 
115.900 ± 
8.949 
TGR 9 
121.060 ± 
7.228 
TGR 9 112.11 ± 6.660 
HBP 
Wild 10 
122.100 ± 
5.896 
HBP 
Wild 10 
111.200 ± 
5.411 
TGR 6 
120.167 ± 
5.913 
TGR 6 
121.833 ± 
7.521 
D-
HBP 
Wild 12 
121.250 ± 
7.375 D-
HBP 
Wild 12 
501.250 ± 
19.749 
TGR 9 
115.556 ± 
9.342 
TGR 9 
479.889 ± 
33.573 
Week-1 
CTRL 
Wild 10 
119.100 ± 
5.820 
Week-5 
CTRL 
Wild 10 
120.700 ± 
9.381 
TGR 9 
122.111 ± 
6.333 
TGR 9 
117.889 ± 
9.771 
HBP 
Wild 10 
119.000 ± 
4.216 
HBP 
Wild 10 
114.900 ± 
6.806 
TGR 6 
119.500 ± 
4.929 
TGR 6 
118.833 ± 
8.998 
D-
HBP 
Wild 12 
480.500 ± 
50.581 D-
HBP 
Wild 12 
500.583 ± 
32.704 
TGR 9 
463.778 ± 
41.686 
TGR 9 
483.000 ± 
35.889 
Week-2 
CTRL 
Wild 10 
120.100 ± 
9.386 
Week-6 
CTRL 
Wild 10 
117.700 ± 
8.858 
TGR 9 
124.889 ± 
7.991 
TGR 9 
113.889 ± 
10.142 
HBP 
Wild 10 
120.500 ± 
9.641 
HBP 
Wild 10 
117.000 ± 
6.960 
TGR 6 
120.500 ± 
11.327 
TGR 6 
125.167 ± 
9.948 
D-
HBP 
Wild 12 
474.667 ± 
33.285 D-
HBP 
Wild 12 
519.500 ± 
41.478 
TGR 9 
452.444 ± 
24.259 
TGR 9 
479.667 ± 
17.263 
Week-3 
CTRL 
Wild 10 
117.800 ± 
7.685 
Week-7 
CTRL 
Wild 10 
119.600 ± 
2.252 
TGR 9 
117.667 ± 
9.219 
TGR 9 
119.000 ± 
9.734 
HBP 
Wild 10 
122.300 ± 
6.533 
HBP 
Wild 10 
115.400 ± 
9.047 
TGR 6 
125.933 ± 
6.210 
TGR 6 
118.167 ± 
9.261 
D-
HBP 
Wild 12 
520.750 ± 
52.678 D-
HBP 
Wild 12 
521.167 ± 
38.076 
TGR 9 
492.889 ± 
39.072 
TGR 9 
483.111 ± 
19.971 
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Appendix-B: Urine production at the beginnig of the experiment and at the end of the experiment. 
Wild=Wild Type, TGR=Transgenic, CTRL= Control rats, HBP= Rats fed by the pellet food with I3C, D-
HBP=Diabetic rats fed by the pellet food with I3C, N =number of rats in the group. 
 
Sex Age 
(weeks) 
Group Genotype N Urine Produced 
[mL/24] 
Male Week-0 CTRL Wild 10 13.5480 ± 5.56 
TGR 9 13.9522 ± 2.01   
HBP Wild 10 10.7890  ± 3.31 
TGR 6 12.9140 ± 1.14 
D-HBP Wild 12 10.8533  ± 1.01 
TGR 9 9.7400  ± 3.70 
Week-7 CTRL Wild 10 13.046 ± 5.25 
TGR 9 14.462 ± 2.81 
HBP Wild 10 11.223 ± 3.04 
TGR 6 16.59 ± 2.87 
D-HBP Wild 12 233.81 ± 40.70 
TGR 9 192.151 ± 37.57 
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Appendix-C: Water Consumption. Wild=Wild Type, TGR=Transgenic, CTRL= Control rats, HBP= 
Rats fed by the pellet food with I3C, D-HBP=Diabetic rats fed by the pellet food with I3C, N =number 
of rats in the group. 
 
Sex Age 
(weeks) 
Group Genotype N Water Consumption 
[mL] 
Male Week-0 CTRL Wild 10 24.68 ± 5.93 
TGR 9 26.26 ± 4.16 
HBP Wild 10 23.37 ± 8.83 
TGR 6 25.69 ± 2.17 
D-HBP Wild 12 26.36 ± 2.72 
TGR 9 24.94 ± 2.62 
Week-2 CTRL Wild 10 23.71 ± 4.90 
TGR 9 26.62 ± 3.72 
HBP Wild 10 28.83 ± 4.83 
TGR 6 32.22 ± 1.61 
D-HBP Wild 12 239.34 ± 27.45 
TGR 9 249.93 ± 41.35 
Week-7 CTRL Wild 10 23.54 ± 8.48 
TGR 9 24.28 ± 4.46 
HBP Wild 10 27.71 ± 4.83 
TGR 6 30.53 ± 4.47 
D-HBP Wild 12 201.34 ± 71.52 
TGR 9 199.05 ± 31.05 
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Appendix-D: Blood Pressure. Wild=Wild Type, TGR=Transgenic, CTRL= Control rats, HBP= Rats fed 
by the pellet food with I3C, D-HBP=Diabetic rats fed by the pellet food with I3C, N =number of rats in 
the group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sex Age Group Genotype N Blood Pressure 
[mmHg] 
Male Week-0 CTRL Wild 10 122.100 ± 4.306 
TGR 9 123.444 ± 7.367 
HBP Wild 10 130.300 ± 9.441 
TGR 6 123.167 ± 6.795 
D-HBP Wild 12 131.667 ± 6.513 
TGR 9 126.889 ± 8.300 
Week-2 CTRL Wild 10 122.600 ± 5.038 
TGR 9 124.000 ± 9.093 
HBP Wild 10 168.700 ± 6.816 
TGR 6 165.167 ± 6.178 
D-HBP Wild 12 175.417 ± 6.973 
TGR 9 170.222 ± 10.244 
Week-4 CTRL Wild 10 125.200 ± 5.594 
TGR 9 129.556 ± 6.691 
HBP Wild 10 184.500 ± 4.301 
TGR 6 163.500 ± 6.221 
D-HBP Wild 12 177.000 ± 11.086 
TGR 9 172.001 ± 11.023 
Week-6 CTRL Wild 10 129.100 ± 4.383 
TGR 9 128.333 ± 9.179 
HBP Wild 10 179.100 ± 6.522 
TGR 6 167.000 ± 7.616 
D-HBP Wild 12 171.583 ± 5.616 
TGR 9 170.778 ± 6.553 
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Appendix-E: FITC-sinistrin half-life (Transcutaneous GFR measurement). Wild=Wild Type, 
TGR=Transgenic, CTRL= Control rats, HBP= Rats fed by the pellet food with I3C, D-HBP=Diabetic 
rats fed by the pellet food with I3C, N =number of rats in the group. 
 
Sex Age 
(weeks) 
Group Genotype N FITC-Sinistrin halflife 
[minutes] 
Male Week-2 CTRL Wild 3 23.07 ± 1.93 
TGR 3 29.38 ± 5.18 
HBP Wild NA NA 
TGR 4 22.65 ± 8.07 
D-HBP Wild 4 46.32 ± 13.32 
TGR 4 24.24 ± 15.74 
Week-6 CTRL Wild 3 26.51 ± 5.46  
TGR 3 25.35 ± 10.56 
HBP Wild NA NA 
TGR 4 56.83 ± 6.91 
D-HBP Wild 4 112.17 ± 28.78 
TGR 4 187.96 ± 55.46 
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Appendix-F: Urinary Protein and Albumin (mg/24). Wild=Wild Type, TGR=Transgenic, CTRL= Control 
rats, HBP= Rats fed by the pellet food with I3C, D-HBP=Diabetic rats fed by the pellet food with I3C, N 
=number of rats in the group. 
 
Sex Age 
(weeks) 
Group Genotype N Protein Albumin 
[mg/24] [mg/24] 
Male Week-7 CTRL Wild 10 3.20 ± 2.78 0.33 ± 0.178 
TGR 9 8.66 ± 1.11 4.33 ± 1.67 
HBP Wild 10 10.80 ± 1.55 4.08 ± 2.33 
TGR 6 84.33 ± 12.55 51.92 ± 10.96 
D-HBP Wild 12 262.58 ± 8.38 178.26 ± 32.67 
TGR 9 536.50 ± 33.41 354.92 ± 49.40 
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Appendix-G: Plasma Urea, Creatinine, Triglyceride and Cholesterol Concentration. Wild=Wild Type, 
TGR=Transgenic, CTRL= Control rats, HBP= Rats fed by the pellet food with I3C, D-HBP=Diabetic 
rats fed by the pellet food with I3C, N =number of rats in the group. 
 
Sex Age 
(weeks) 
Group Genotype N Plasma Urea 
Concentration 
Plasma 
Creatinine 
Concentration 
Plasma 
Triglyceride 
Concentration 
Plasma 
Cholesterol 
Concentration 
[mg/dL] [mg/dL] [mg/dL] [mg/dL] 
Male Week-7 CTRL Wild 10 34.84 ± 2.25 0.27 ± 0.030 149 ± 24.02 85.33 ± 6.58 
TGR 9 33.26 ± 2.28 0.29 ± 0.027 191.33 ± 34.77 79.22 ± 15.22 
HBP Wild 10 33.63 ± 4.38 0.29 ± 0.024 91.80 ± 28.14 86.20 ± 27.17 
TGR 6 32.83 ± 1.70 0.24 ± 0.013 278.67 ± 67.59 160.33 ±21.29 
D-HBP Wild 12 50.26 ± 8.78 0.15 ± 0.016 488.78 ± 167.5 263.44 ±83.81 
TGR 9 49.85 ± 5.84 0.16 ± 0.009 404.38 ± 145.6 422.5 ±110.83 
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Appendix-H: Body Weight, Kidney weight, Kidney/Body Weight and Glomerular Area. Wild=Wild 
Type, TGR=Transgenic, CTRL= Control rats, HBP= Rats fed by the pellet food with I3C, D-
HBP=Diabetic rats fed by the pellet food with I3C, N =number of rats in the group. 
 
Sex Age 
(weeks) 
Group Genotype N Body Weight Kidney Weight Glomerular area 
[g] [g] [µm^2] 
Male Week-7 CTRL Wild 10 381.67 ± 36.09 1.41 ± 0.20 10464.8 ± 1791.62 
TGR 9 381.67 ± 17.76 1.55 ± 0.38 10279.0 ± 3244.50 
HBP Wild 10 345.70 ± 18.15 1.64 ± 0.19 12303.1 ± 2527.27  
TGR 6 402.58 ± 20.55 1.52 ± 0.16 14623.5 ± 3335.08 
D-HBP Wild 12 228.35 ± 50.22 1.54 ± 0.24 13412.4 ± 2611.84 
TGR 9 259.38 ± 84.78 1.43 ± 0.23 14869.7 ± 3109.28 
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